0001493152-23-018333.txt : 20230519 0001493152-23-018333.hdr.sgml : 20230519 20230519161548 ACCESSION NUMBER: 0001493152-23-018333 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 42 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230519 DATE AS OF CHANGE: 20230519 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jupiter Wellness Acquisition Corp. CENTRAL INDEX KEY: 0001883799 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 872646504 STATE OF INCORPORATION: E9 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41126 FILM NUMBER: 23940251 BUSINESS ADDRESS: STREET 1: 1061 E. INDIANTOWN ROAD, SUITE 110 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: 5614622700 MAIL ADDRESS: STREET 1: 1061 E. INDIANTOWN ROAD, SUITE 110 CITY: JUPITER STATE: FL ZIP: 33477 10-Q 1 form10-q.htm
0001883799 false --09-30 2023 Q2 0001883799 2022-10-01 2023-03-31 0001883799 JWAC:ClassCommonStockParValue0.0001PerShareMember 2022-10-01 2023-03-31 0001883799 JWAC:RightsExchangeableForOneeighthOfOneShareOfClassCommonStockMember 2022-10-01 2023-03-31 0001883799 us-gaap:CommonClassAMember 2023-05-19 0001883799 us-gaap:CommonClassBMember 2023-05-19 0001883799 2023-03-31 0001883799 2022-09-30 0001883799 us-gaap:RelatedPartyMember 2023-03-31 0001883799 us-gaap:RelatedPartyMember 2022-09-30 0001883799 us-gaap:CommonClassAMember 2023-03-31 0001883799 us-gaap:CommonClassAMember 2022-09-30 0001883799 us-gaap:CommonClassBMember 2023-03-31 0001883799 us-gaap:CommonClassBMember 2022-09-30 0001883799 2021-10-01 2022-03-31 0001883799 2023-01-01 2023-03-31 0001883799 2022-01-01 2022-03-31 0001883799 us-gaap:CommonClassAMember 2022-10-01 2023-03-31 0001883799 us-gaap:CommonClassAMember 2021-10-01 2022-03-31 0001883799 us-gaap:CommonClassAMember 2023-01-01 2023-03-31 0001883799 us-gaap:CommonClassAMember 2022-01-01 2022-03-31 0001883799 us-gaap:CommonClassBMember 2022-10-01 2023-03-31 0001883799 us-gaap:CommonClassBMember 2021-10-01 2022-03-31 0001883799 us-gaap:CommonClassBMember 2023-01-01 2023-03-31 0001883799 us-gaap:CommonClassBMember 2022-01-01 2022-03-31 0001883799 us-gaap:PreferredStockMember 2021-09-30 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-09-30 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-09-30 0001883799 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001883799 us-gaap:RetainedEarningsMember 2021-09-30 0001883799 2021-09-30 0001883799 us-gaap:PreferredStockMember 2021-12-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-12-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-12-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001883799 us-gaap:RetainedEarningsMember 2021-12-31 0001883799 2021-12-31 0001883799 us-gaap:PreferredStockMember 2022-09-30 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-09-30 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-09-30 0001883799 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001883799 us-gaap:RetainedEarningsMember 2022-09-30 0001883799 us-gaap:PreferredStockMember 2022-12-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-12-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-12-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001883799 us-gaap:RetainedEarningsMember 2022-12-31 0001883799 2022-12-31 0001883799 us-gaap:PreferredStockMember 2021-10-01 2021-12-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-10-01 2021-12-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-10-01 2021-12-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001883799 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001883799 2021-10-01 2021-12-31 0001883799 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-01-01 2022-03-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-01-01 2022-03-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001883799 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001883799 us-gaap:PreferredStockMember 2022-10-01 2022-12-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-10-01 2022-12-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-10-01 2022-12-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001883799 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001883799 2022-10-01 2022-12-31 0001883799 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-01-01 2023-03-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-01-01 2023-03-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001883799 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001883799 us-gaap:PreferredStockMember 2022-03-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-03-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-03-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001883799 us-gaap:RetainedEarningsMember 2022-03-31 0001883799 2022-03-31 0001883799 us-gaap:PreferredStockMember 2023-03-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-03-31 0001883799 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-03-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001883799 us-gaap:RetainedEarningsMember 2023-03-31 0001883799 us-gaap:IPOMember 2021-12-08 2021-12-09 0001883799 2021-12-09 0001883799 us-gaap:OverAllotmentOptionMember 2021-12-08 2021-12-09 0001883799 2021-12-08 2021-12-09 0001883799 JWAC:PostTransactionMember 2021-12-09 0001883799 JWAC:AmericanStockTransferAndTrustCompanyLLCMember 2021-12-09 0001883799 us-gaap:CommonClassAMember 2021-12-09 0001883799 us-gaap:IPOMember 2021-12-09 0001883799 2022-10-26 0001883799 JWAC:SellerMember 2022-10-26 0001883799 JWAC:EarnoutParticipantsMember 2022-10-26 0001883799 JWAC:ChijetMotorCompanyIncMember 2022-12-05 0001883799 2022-12-05 0001883799 JWAC:JupiterWellnessAcquisitionCorpMember 2023-03-06 0001883799 2023-03-06 0001883799 srt:ScenarioForecastMember 2023-03-09 2023-06-08 0001883799 srt:ScenarioForecastMember 2023-06-08 0001883799 2021-09-19 2021-09-20 0001883799 us-gaap:CommonClassBMember 2021-12-01 2021-12-31 0001883799 us-gaap:CommonClassBMember 2021-12-31 0001883799 us-gaap:CommonClassBMember 2021-12-08 2021-12-09 0001883799 us-gaap:CommonClassBMember 2021-12-09 0001883799 us-gaap:PrivatePlacementMember 2021-12-08 2021-12-09 0001883799 srt:ChiefFinancialOfficerMember 2022-10-01 2022-12-31 0001883799 JWAC:ManagmentAndDirectorsMember us-gaap:RelatedPartyMember 2023-03-31 0001883799 JWAC:ManagmentAndDirectorsMember us-gaap:RelatedPartyMember 2022-09-30 0001883799 JWAC:UnsecuredPromissoryNoteMember JWAC:JupiterWellnessInvestmentCorpMember 2023-03-06 0001883799 JWAC:UnsecuredPromissoryNoteMember JWAC:JupiterWellnessInvestmentCorpMember 2023-03-08 0001883799 JWAC:DirectorsAndOfficersMember 2021-12-08 2021-12-09 0001883799 JWAC:ChijetMotorCompanyIncMember JWAC:UnsecuredPromissoryNoteMember 2022-12-05 0001883799 JWAC:ChijetMotorCompanyIncMember JWAC:UnsecuredPromissoryNoteMember 2023-03-06 0001883799 us-gaap:CommonStockMember 2023-03-31 0001883799 us-gaap:CommonClassBMember 2021-10-01 2022-09-30 0001883799 JWAC:RepresentativeWarrantsMember 2021-12-08 2021-12-09 0001883799 JWAC:RepresentativeWarrantsMember 2021-12-09 0001883799 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-09 0001883799 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-09 0001883799 us-gaap:MeasurementInputExpectedTermMember 2021-12-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to ______

 

Commission File No. 001-41126

 

JUPITER WELLNESS ACQUISITION CORP.
(Exact name of registrant as specified in its charter)

 

Delaware   87-2646504
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer
Identification No.)

 

1061 E. Indiantown Road, Suite 110

Jupiter, Florida 33477

(Address of Principal Executive Offices, including zip code)
 
(561) 244-7100
(Registrant’s telephone number, including area code)
 
N/A
(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A common stock, par value $0.0001 per share   JWAC   The Nasdaq Stock Market LLC
Rights, exchangeable for one-eighth of one share of Class A common stock   JWACR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  ☐ Large accelerated filer ☐ Accelerated filer
  ☒ Non-accelerated filer ☒ Smaller reporting company
    ☒ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☒ No ☐

 

As of May 19, 2023, there were 14,705,000 shares of Class A common stock and 3,450,000 shares of Class B common stock, $0.0001 par value, issued and outstanding.

 

 

 

 

 

 

JUPITER WELLNESS ACQUISITION CORP.
FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2023
TABLE OF CONTENTS

 

    Page
PART I – FINANCIAL INFORMATION 1
     
Item 1. Financial Statements 1
     
  Balance Sheets (unaudited) 1
     
  Statements of Operations (unaudited) 2
     
  Statements of Changes in Stockholder’s (Deficit) (unaudited) 3
     
  Statements of Cash Flows (unaudited) 4
     
  Notes to Financial Statements (unaudited) 5
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 17
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 19
     
Item 4. Control and Procedures 19
     
PART II – OTHER INFORMATION 20
     
Item 1. Legal Proceedings 20
     
Item 1A. Risk Factors 20
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20
   
Item 3. Defaults Upon Senior Securities 20
     
Item 4. Mine Safety Disclosures 20
     
Item 5. Other Information 20
     
Item 6. Exhibits 20
     
SIGNATURES 21

 

i

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. FINANCIAL STATEMENTS

 

JUPITER WELLNESS ACQUISITION CORP.

Balance Sheets

 

 

   March 31, 2023   September 30, 2022 
   (Unaudited)     
Assets          
Current assets          
Cash  $17,731   $610,382 
Prepaid expense   112,529    251,085 
Cash and marketable securities held in Trust Account   145,433,953    140,173,416 
Total current assets   145,564,213    141,034,883 
           
Total assets  $145,564,213   $141,034,883 
           
Liabilities and Stockholders’ (Deficit)          
Current Liabilities          
Accrued expense-related party  $13,667   $8,667 
Accrued expense   145,000    40,000 
Franchise tax Payable   50,000    - 
Income tax Payable   546,123    - 
Deferred underwriting fee   4,830,000    4,830,000 
Promissory Note - related party   300,000    - 
Extension loan   2,560,000    - 
Total current liabilities   8,444,790    4,878,667 
           
Total liabilities   8,444,790    4,878,667 
           
Commitments          
Common stock subject to possible redemption   144,837,830    139,973,416 
           
Stockholders’ (Deficit)          
Preferred stock, $0.0001 par value, 1,000,000 shares authorized, -0- shares issued and outstanding   -    - 
Class A Common stock, $0.0001 par value, 100,000,000 shares authorized, 905,000 issued and outstanding as of March 31, 2023 and September 30, 2022   91    91 
Class B Common stock, $0.0001 par value, 10,000,000 shares authorized, 3,450,000 issued and outstanding as of March 31, 2023 and September 30, 2022   345    345 
Additional paid in capital   -    - 
Accumulated (deficits)   (7,718,843)   (3,817,636)
Total Stockholders’ (Deficit)   (7,718,407)   (3,817,200)
           
Total Liabilities and Stockholders’ (Deficit)  $145,564,213   $141,034,883 

 

The accompanying notes are an integral part of these unaudited financial statements

 

1

 

 

JUPITER WELLNESS ACQUISITION CORP.

Statements of Operations

 

 

   2023   2022   2023   2022 
  

For the Six Months Ended

March 31,

  

For the Three Months Ended

March 31,

 
   2023   2022   2023   2022 
                 
Operating expense                    
Officers compensation  $30,000   $18,667   $15,000   $8,667 
Franchise Tax   100,000    -    50,000    - 
General and administrative expenses   1,261,207    346,489    1,155,037    230,366 
Total operating expense   1,391,207    365,156    1,220,037    239,033 
                     
Other Income/(Expense), net   2,700,587    (12,845)   1,518,128    (13,391)
                     
Net Income (loss) before income tax   1,309,380    (378,001)   298,091    (252,424)
                     
Income Tax   (546,123)   -    (308,307)   - 
                     
Net Income (loss)  $763,257   $(378,001)  $(10,216)   $(252,424)
                     
Net income (loss) per share:                    
Weighted average shares outstanding, basic and dilutive                    
Class A - Common stock   14,705,000    9,049,231    14,705,000    14,705,000 
Class B - Common stock   3,450,000    3,238,324    3,450,000    3,450,000 
                     
Basic and diluted net income (loss) per share                    
Class A - Common stock  $0.04   $(0.03)  $(0.00)  $(0.01)
Class B - Common stock  $0.04   $(0.03)  $(0.00)   $(0.01)

 

The accompanying notes are an integral part of these unaudited financial statements

 

2

 

 

JUPITER WELLNESS ACQUISITION CORP.

Statements of Changes in Stockholders’ (Deficit)

 

 

   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficits   Total 
   Preferred Stock  

Class A

Common Stock

  

Class B

Common Stock

   Additional Paid-in   Accumulated     
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficits   Total 
Balance, September 30, 2021   —   $—    —   $—    3,450,000   $345   $49,655   $(21,015)  $28,985 
                                              
Sale of 13,800,000 Units at IPO   —    —    13,800,000    1,380    —    —    137,998,620    —    138,000,000 
                                              
Offering Cost-Funds Flow   —    —    —    —    —    —    (3,155,917)   —    (3,155,917)
                                              
Class A units issued for Representative shares   —    —    276,000    28    —    —    (28)   —    — 
                                              
Deferred underwriting fee   —    —    —    —    —    —    (4,830,000)   —    (4,830,000)
                                              
Sale of 629,000 private units   —    —    629,000    63    —    —    6,289,937    —    6,290,000 
                                              
Common stock subject to possible redemption   —    —    (13,800,000)   (1,380)   —    —    (139,378,620)   —    (139,380,000)
                                              
Reclassification from negative additional paid-in capital to accumulated deficit   —    —    —    —    —    —    3,026,353    (3,026,353)   — 
                                              
Net loss   —    —    —    —    —    —    —    (125,577)   (125,577)
                                              
Balance, December 31, 2021   —   $—    905,000   $91    3,450,000   $345   $—   $(3,172,945)  $(3,172,509)
                                              
Net loss   —    —    —    —    —    —    —    (252,424)   (252,424)
                                              
Balance, March 31, 2022   —   $—    905,000   $91    3,450,000   $345   $—   $(3,425,369)  $(3,424,933)
                                              
Balance, September 30, 2022   —   $—    905,000   $91    3,450,000   $345   $—   $(3,817,636)  $(3,817,200)
                                              
Additional amount deposited into trust   —    —    —    —    —    —    —    (1,380,000)   (1,380,000)
                                              
Accretion for Class A common stock to redemption amount   —    —    —    —    —    —    —    (1,182,459)   (1,182,459)
                                              
Net loss   —    —    —    —    —    —    —    773,473    773,473 
                                              
Balance, December 31, 2022   —   $—    905,000   $91    3,450,000   $345   $—   $(5,606,622)  $(5,606,186)
                                              
Additional amount deposited into trust   —    —    —    —    —    —    —    (1,180,000)   (1,180,000)
                                              
Accretion for Class A common stock to redemption amount   —    —    —    —    —    —    —    (922,005)   (922,005)
                                              
Net loss   —    —    —    —    —    —    —    (10,216)   (10,216) 
                                              
Balance, March 31, 2023   —   $—    905,000   $91    3,450,000   $345   $—   $(7,718,843)  $(7,718,407)

 

The accompanying notes are an integral part of these unaudited financial statements

 

3

 

 

JUPITER WELLNESS ACQUISITION CORP.

Statements of Cash Flows

 

 

   2023   2022 
   For the Six Months Ended March 31, 
   2023   2022 
         
Cash flows from operating activities:          
Net Income (loss)  $763,257   $(378,001)
Adjustments to reconcile net income to net cash          
Interest earned on marketable securities held in Trust Account   (2,700,587)   (13,952)
Unrealized loss from the trust account   -    26,797 
Changes in operating assets and liabilities:          
Franchise tax payable   50,000    - 
Income tax payable   546,123    - 
Prepaid expense   138,556    (253,119)
Accrued expense-related party   5,000    18,667 
Accrued expense   105,000    99,687 
Net cash (used in) operating activities   (1,092,651)   (499,921)
           
Cash flows from investing activities:          
Investment of cash in Trust Account   (2,360,000)   (139,380,000)
Net cash (used in) financing activities   (2,360,000)   (139,380,000)
           
Cash flows from financing activities:          
Proceeds from sale of Units, net of underwriting discounts and offering expenses paid   -    134,844,083 
Proceeds from sale of private units   -    6,290,000 
Proceeds from note payable   2,560,000    - 
Proceeds (Repayment) to notes payable - related parties   300,000    (371,650)
Net cash provided by financing activities   2,860,000    140,762,433 
           
Net increase/(decrease) in cash and cash equivalents   (592,651)   882,512 
           
Cash and cash equivalents at the beginning of the period   610,382    363,135 
           
Cash and cash equivalents at the end of the period  $17,731   $1,245,647 
           
SUPPLEMENTAL CASH FLOW INFORMATION:          
Cash paid for interest  $-   $- 
Cash paid for income taxes  $-   $- 
           
Non-Cash investing and financing activities:          
Funds attributable to common stock subject to redemption  $

2,560,000

   $- 
Initial classification of ordinary shares subject to possible redemption  $-   $139,380,000 
Deferred Underwriting Fee  $-   $4,830,000 
Accretion for Class A common stock to redemption amount  $2,104,464   $- 

 

The accompanying notes are an integral part of these unaudited financial statements

 

4

 

 

JUPITER WELLNESS ACQUISITION CORP.

Notes to Financial Statements

March 31, 2023

(UNAUDITED)

 

Note 1 — ORGANIZATION AND BUSINESS OPERATIONS

 

Jupiter Wellness Acquisition Corporation (the “Company”) is a blank check company incorporated on September 14, 2021, under the laws of the State of Delaware for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (a “Business Combination”). On October 26, 2022, the Company identified a target company for a Business Combination and activities in connection with the proposed acquisition of Chijet Inc., a Cayman Islands exempted company (see Note 4). The Company will not generate any operating revenues until after consummation of the initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the IPO.

 

As of March 31, 2023, the Company had not yet commenced any operations. All activity as of March 31, 2023, relates to the Company’s formation and the initial Public Offering (as defined below). The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected September 30 as its fiscal year end.

 

On December 9, 2021, the Company consummated its IPO of 13,800,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units, the “Public Shares”) at $10.00 per unit, which included 1,800,000 Units issued pursuant to the full exercise by the Underwriters (as defined below) of their over-allotment option, and the private sale of an aggregate of 629,000 Units (the “Private Placement Units” and with respect to the shares of Class A common stock included in the Units, the “Private Placement Shares”) to its sponsor, Jupiter Wellness Sponsor LLC (the “Sponsor”) and I-Bankers Securities, Inc. (“I-Bankers”) at a purchase price of $10.00 per Private Placement Unit, generating gross proceeds of $6,290,000 to the Company that closed simultaneously with the closing of the IPO (see Note 3). The Company’s Units have been listed on the Nasdaq Global Market (“Nasdaq”).

 

Transaction costs amounted to $7,985,917 consisting of $2,760,000 in cash of underwriting commissions, $4,830,000 of business combination marketing fee, and $395,917 of other offering costs. In addition, as of December 9, 2021, cash of $1,630,676 was held outside of the Trust Account (as defined below) and is available for working capital purposes.

 

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete a Business Combination with one or more operating businesses or assets that together have an aggregate fair market value equal to at least 80% of the net assets held in the Trust Account (net of amounts disbursed to management for working capital purposes, if permitted, and excluding the amount of any deferred underwriting commissions) at the time of the Company’s signing a definitive agreement in connection with its initial Business Combination. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires an interest in the target business or assets sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”).

 

Upon the closing of the IPO on December 9, 2021, the Company deposited $139,380,000 ($10.10 per Unit) from the proceeds of the IPO and certain proceeds of the sales of Private Placement Units in the trust account (“Trust Account”), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below.

 

5

 

 

The Company will provide its stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account (initially $10.10 per share), calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The shares of Class A common stock will be recorded at redemption value and classified as temporary equity upon the completion of the IPO, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”

 

The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 upon such completion of a Business Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination.

 

If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to (i) waive its redemption rights with respect to their Private Placement Shares in connection with the completion of the Business Combination, (ii) waive its redemption rights with respect to their Private Placement Shares in connection with a stockholder vote to approve an amendment to the Company’s second amended and restated certificate of incorporation (a) to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares if the Company does not complete the Business Combination within the Combination Period (as defined below) or (b) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination activity and (iii) waive its rights to liquidating distributions from the Trust Account with respect to their Private Placement Shares if the Company fails to complete the Business Combination within the Combination Period. In addition, the Sponsor has agreed to vote any share it held in favor of the Business Combination.

 

Additionally, each public stockholder may elect to redeem its Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination.

 

Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s second amended and restated certificate of incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares without the Company’s prior written consent.

 

The Company will have until 12 months from the closing of the IPO (or 18 months from the closing of the IPO if the Company may extend the period of time to consummate a Business Combination) (the “Combination Period”) to complete a Business Combination. If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than 10 business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (less up to $50,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and requirements of other applicable law. On December 6, 2022, the Company extended the Combination Period until March 8, 2023. On March 6, 2023, the Company deposited another extension payment to extend the Combination Period until June 8, 2023.

 

The Sponsor has agreed to waive its liquidation rights with respect to the Founder Shares (as defined below) and Private Placement Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor acquires Public Shares in or after the IPO, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their business combination marketing fees (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the IPO price per Unit ($10.10).

 

6

 

 

The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a third party for services rendered or products sold to the Company, or by a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.10 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent auditors), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

 

Underwriting Agreement and Business Combination Marketing Agreement

 

The Company engaged I-Bankers as the representative of the underwriters (the “Underwriters”) in the IPO of the Company’s Class A common stock, par value of $0.0001 per share (“Shares”), for $120 million and the simultaneous listing on Nasdaq. Pursuant to that certain underwriting agreement, I-Bankers acted as the representative of the Underwriters of the IPO for 12,000,000 Units at $10.00 per unit, plus an over-allotment option equal to 15% of the number of Units offered, or 1,800,000 Units, which was exercised in full simultaneously upon the closing of the IPO. The Company paid I-Bankers underwriters’ commission of $2,760,000, equal to 2.0% of the gross proceeds raised in the IPO for such services upon the consummation of the IPO (exclusive of any applicable finders’ fees which might become payable).

 

Upon the closing of the IPO, the Company issued to I-Bankers a five-year warrant to purchase 414,000 Shares of Class A common stock, equal to 3.0% of the Shares issued in the IPO (“Representative Warrants”). The exercise price of Representative Warrants is $12.00 per Share. In addition, I-Bankers was issued 276,000 shares of Class A common stock upon the consummation of IPO (“Representative Shares”).

 

In addition, under a business combination marketing agreement, the Company has engaged I-Bankers as an advisor in connection with the Business Combination and will pay I-Bankers a cash fee for such marketing services upon the consummation of the Business Combination in an amount equal to, in the aggregate, 3.5% of the gross proceeds of the IPO, including any proceeds from the exercise of the underwriters’ over-allotment option. The fee will become payable to the Underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

 

Going Concern Consideration

 

The Company expects to incur significant costs in pursuit of its financing and acquisition plans. In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that if the Company is unsuccessful in consummating an initial business combination within the prescribed period of time from the closing of the IPO, the requirement that the Company cease all operations, redeem the public shares and thereafter liquidate and dissolve raises substantial doubt about the ability to continue as a going concern. The balance sheet does not include any adjustments that might result from the outcome of this uncertainty. Management has determined that the Company has funds that are sufficient to fund the working capital needs of the Company until the consummation of an initial business combination or the winding up of the Company as stipulated in the Company’s amended and restated memorandum of association. The accompanying financial statement has been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern.

 

7

 

 

Risks and Uncertainties

 

Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a target company, the specific impact is not readily determinable as of the date of this financial statement. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of US Securities and Exchange Commission (“SEC”).

 

Emerging Growth Company Status

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act and modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company had $17,731 in cash as of March 31, 2023. The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2023.

 

8

 

 

Marketable Securities Held in Trust Account

 

At March 31, 2023, substantially all of the assets held in the Trust Account were held in money market funds which are invested primarily in U.S. Treasury securities. All of the Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. At March 31, 2023, $145,433,953 was held in the Trust Account.

 

Offering Costs Associated with the IPO

 

The Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the IPO that were directly related to the IPO. The Company incurred offering costs amounting to $7,985,917 as a result of the IPO consisting of $2,760,000 in cash of underwriting commissions, $4,830,000 of business combination marketing fee, and $395,917 of other offering costs. As of March 31, 2023, offering costs in the aggregate of $3,155,917 have been charged to stockholders’ equity and $4,830,000 have been classified to current liabilities, respectively.

 

Class A Common Stock Subject to Possible Redemption

 

All of the 13,800,000 shares of Class A common stock sold as part of the Units in the IPO contain a redemption feature. In accordance with the Accounting Standards Codification 480-10-S99-3A “Classification and Measurement of Redeemable Securities”, redemption provisions not solely within the control of the Company require the security to be classified outside of permanent equity. Ordinary liquidation events, which involve the redemption and liquidation of all of the entity’s equity instruments, are excluded from the provisions of ASC 480. The change in the carrying value of redeemable shares of common stock resulted in charges against additional paid-in capital and accumulated deficit. Accordingly, at March 31, 2023, the shares of Class A common stock subject to possible redemption in the amount of $144,837,830 were presented as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the federal depository insurance coverage corporation limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 

Fair Value of Financial Instruments

 

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.

 

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 

  ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;
     
  ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
     
  ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

9

 

 

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

 

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.

 

Business Combination Marketing Fee

 

Pursuant to the business combination marketing agreement, the Company has engaged I-Bankers as an advisor in connection with the Business Combination and will pay I-Bankers a cash fee for such marketing services upon the consummation of the Business Combination in an amount equal to, in the aggregate, 3.5% of the gross proceeds of the IPO, including any proceeds from the full or partial exercise of the underwriters’ over-allotment option.

 

Stock-Based Compensation

 

The Company recognizes compensation costs to employees under FASB Accounting Standards Codification 718 “Compensation – Stock Compensation” (“ASC 718”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

 

On September 14, 2021, the inception date, the Company adopted Accounting Standards Update (“ASU”) No. 2018-07 “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation – Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned.

 

Income Taxes

 

The Company complies with the accounting and reporting requirements of FASB ASC, 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. There were no unrecognized tax benefits as of March 31, 2023 and September 30, 2022. Deferred tax assets were deemed to be de minimis as of March 31, 2023 and September 30, 2022.

 

FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at March 31, 2023 and September 30, 2022.

 

Income taxes was accrued for $546,123 and $308,307 for the six and three months ended March 31, 2023, respectively.

 

10

 

 

Warrants

 

ASC 480 requires a reporting entity to classify certain freestanding financial instruments as liabilities (or in some cases as assets). ASC 480-10-S99 addresses concerns raised by the SEC regarding the financial statement classification and measurement of securities subject to mandatory redemption requirements or whose redemption is outside the control of the issuer. If the stock subject to mandatory redemption provisions represents the only shares in the reporting entity, it must report instruments in the liabilities section of its statement of financial position. The stock subject must then describe them as shares subject to mandatory redemption, so as to distinguish the instruments from other financial statement liabilities. The Company concludes that the warrants to I-Bankers do not exhibit any of the above characteristics and, therefore, are outside the scope of ASC 480. The warrants were issued in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging — Contracts in Entity’s Own Equity. Such guidance provides that because the warrants meet the criteria for equity treatment.

 

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statement.

 

NOTE 3 — Public Offering

 

At the IPO, the Company sold 13,800,000 Units at a purchase price of $10.00 per Unit, which included 1,800,000 Units issued pursuant to the full exercise by the Underwriters of their over-allotment option, generating gross proceeds to the Company of $138,000,000. Each Unit consists of one share of Class A common stock of the Company, par value $0.0001 per share (“Class A common stock”), and one right to receive one-eighth of one share of Class A common stock upon the consummation of the Company’s initial business combination (see Note 6).

 

A total of $139,380,000 of the net proceeds from the IPO and the sale of the Private Placement Units was placed in a U.S.-based Trust Account maintained by American Stock Transfer & Trust Company, LLC, acting as trustee.

 

NOTE 4 — BUSINESS COMBINATION

 

On October 26, 2022, Jupiter Wellness Acquisition Corp., a blank check, special purpose acquisition company incorporated as a Delaware corporation (the “Company”), issued a press release (the “Press Release”) announcing that the Company has entered into a definitive Business Combination Agreement (the “BCA”) on October 25, 2022, with Chijet Inc., a Cayman Islands exempted company (together with its subsidiaries, “Chijet”), each of the referenced holders of Chijet’s outstanding capital shares (collectively, the “Sellers”) and certain other parties formed in connection with the transactions contemplated by the BCA (the “Business Combination”), including Chijet Motor Company, Inc., a Cayman Islands exempted company and a wholly owned subsidiary of Chijet (“Pubco”). Chijet indirectly holds controlling interests in Shandong Baoya New Energy Vehicle Co., Ltd., a Chinese company (“Baoya”), which is a producer and manufacturer of electric vehicles and FAW Jilin Automobile Co., Ltd., a Chinese company (“FAW Jilin”), which manufactures and sells traditional fuel vehicles.

 

Subject to the terms and conditions of the BCA, Pubco will acquire all of the issued and outstanding shares of Chijet from the Sellers (“Purchased Shares”) in exchange for ordinary shares of Pubco and Chijet shall surrender for no consideration its shares in Pubco, such that Chijet becomes a wholly owned subsidiary of Pubco and the Sellers become shareholders of Pubco (the “Share Exchange”). Immediately thereafter, Merger Sub will merge with and into the Company, with the Company continuing as the surviving entity, as a result of which, (i) the Company shall become a wholly owned subsidiary of Pubco, and (ii) each issued and outstanding security of the Company immediately prior to the consummation of the Business Combination shall no longer be outstanding and shall automatically be cancelled, in exchange for the right of the holder thereof to receive a substantially equivalent security of Pubco (and with the holders of the Company’s publicly traded shares of Class A common stock, par value $0.0001 per share (“Company Class A Common Stock”), that do not redeem their shares also receiving one (1) contingent value right (“CVR,” as defined in the BCA) for each share of Company Class A Common Stock held).

 

11

 

 

Pursuant to the BCA, at the closing, Pubco shall issue and deliver to the Sellers an aggregate number of Pubco ordinary shares (the “Exchange Shares”) with an aggregate value equal to One Billion Six Hundred Million U.S. Dollars ($1,600,000,000), with each Pubco ordinary share valued at the redemption price, and with each Seller receiving its pro rata share of the applicable Exchange Shares based on the number of Purchased Shares owned by such Seller, divided by the total number of purchased shares owned by all Sellers. However, the issuance to certain of the Sellers (the “Earnout Participants”) of Exchange Shares having a value of Six Hundred and Seventy Four Million U.S. Dollars ($674,000,000), with each of such shares being valued at the redemption price (such Pubco ordinary shares, subject to equitable adjustment for share splits, share dividends, combinations, recapitalizations and the like after the closing, including to account for any equity securities into which such shares are exchanged or converted, and together with the earnings thereof, the “Earnout Shares”), and each of the Earnout Participants shall have the contingent right to receive a pro rata portion of such Earnout Shares and earnings thereon (such pro rata allocation based on the number of Purchased Shares owned by such Earnout Participant, divided by the total number of Purchased shares owned by all Earnout Participants) based on Pubco and its subsidiaries achieving certain financial performance metrics over for calendar years 2023, 2024 and 2025 or meeting certain stock price metrics from the closing until 30 trading days after the date on which Pubco files its annual report for the calendar year ended December 31, 2023, 2024 and 2025, respectively with the SEC. To the extent that any such Earnout Shares are not earned, they (along with income thereon) will be redistributed pro rata to the holders of CVRs.

 

On December 5, 2022, the company issued an unsecured promissory note (the “Note”) in the principal amount of $1,380,000 to Chijet (See Note 7 for further discussion.). In connection with the issuance of the Note, on December 5, 2022, the Company deposited an aggregate of $1,380,000 into the trust account of the Company for its public stockholders, which enables the Company to further extend the period of time it has to consummate its initial business combination by three months from December 8, 2022 to March 9, 2023 (the “Extension”). The Extension is the first of up to two three-month extensions permitted under the Company’s governing documents.

 

On March 6, 2023, Jupiter Wellness Acquisition Corp. (the “Company”) issued two unsecured promissory note (the “Note”) in the principal amount totaling of $1,280,000 to Chijet, Inc. In connection with the issuance of the Note, on March 6, 2023, the Company deposited an aggregate of $1,380,000 into the trust account of the Company for its public stockholders, which enables the Company to further extend the period of time it has to consummate its initial business combination by three months from March 9, 2022 to June 8, 2023 (the “Extension”). The Extension is the second of up to two three-month extensions permitted under the Company’s governing documents. The $100,000 balance of the $1,380,000 was funded by the Company itself out of funds available in its operating account.

 

The business combination was not closed as of March 31, 2023.

 

NOTE 5 — RELATED PARTY TRANSACTIONS

 

Founder Shares

 

On September 20, 2021, the Sponsor purchased 2,875,000 shares of the Company’s Class B common stock (the “Founder Shares”) for an aggregate purchase price of $50,000.

 

In December 2021, the Company effected a 0.2 for 1 stock dividend for each share of Class B common stock outstanding (which has been accounted for as a stock split) of 575,000 shares of Class B common stock, which resulted in an aggregate of 3,450,000 shares of Class B common stock outstanding. All share and associated amounts have been retroactively restated to reflect the share dividend.

 

The Founder Shares include an aggregate of up to 450,000 shares of Class B common stock subject to forfeiture by the Sponsor to the extent that the underwriters’ over-allotment is not exercised in full or in part, so that the number of Founder Shares will collectively represent 20% of the Company’s issued and outstanding shares upon the completion of the IPO. On December 9, 2021, the Underwriter exercised the over-allotment option in full. As a result, no Founder Shares is subject to for forfeiture (see Note 3).

 

12

 

 

Private Placement

 

Concurrently with the closing of the IPO, the Sponsor and the Underwriters purchased an aggregate of 629,000 Private Placement Units, generating gross proceeds of $6,290,000 in aggregate in a private placement. Each Private Placement Unit will consist of one share of Class A common stock and one right. Each right underlying the Private Placement Unit (the “Private Placement Right”) will entitle the holder to receive one-eighth of one share of Class A common stock at the closing of a Business Combination. The proceeds from the sale of the Private Placement Units have been added to the net proceeds from the IPO held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Placements Units and all underlying securities will expire worthless.

 

The Private Placement Units (including the underlying Private Placement Rights, the Private Placement Shares and the shares of Class A common stock issuable upon conversion of the Private Placement Rights) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination (except as described under the section of the IPO prospectus entitled “Principal Stockholders — Restrictions on Transfers of Founder Shares and Private Placement Units”). Following such period, the Private Placement Units (including the underlying Private Placement Rights, the Private Placement Shares and the shares of Class A common stock issuable upon conversion of the Private Placement Rights) will be transferable, assignable or salable, except that the Private Placement Units will not trade.

 

Accrued Expenses - Related Parties

 

Pursuant to the executed Offer Letters, the Company agreed to pay the Company’s Chief Financial Officer $5,000 in cash per month starting from December 9, 2021. As of March 31, 2023 and September 30, 2022, the Company had accrued expenses – related parties in amount of $13,667 and $8,667 in connection with the accrued compensation to the Company’s management and directors, respectively.

 

Working Capital Loans

 

In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or certain of the Company’s officers and directors or their affiliates may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into private placement-equivalent units at a price of $10.00 per unit at the option of the lender. Such units would be identical to the Private Placement Units. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of March 31, 2023, no Working Capital Loans were outstanding.

 

Promissory Note - Related Party

 

On March 6, 2023, the Company issued an unsecured promissory note in the principal amount of $100,000 to Jupiter Wellness Investment Corp., a wholly owned subsidiary of Jupiter Wellness, Inc. The Note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.

 

On March 8, 2023, the Company issued an unsecured promissory note in the principal amount of $200,000 to Jupiter Wellness, Inc. This note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.

 

13

 

 

NOTE 6 — COMMITMENTS AND CONTINGENCIES

 

Registration Rights

 

The holders of the Founder Shares, Private Placement Units (and their underlying securities), the Representative Shares, the Representative Warrants (and their underlying securities), the 300,000 shares of Class A common stock issuable to the Company’s directors and officers within 10 days following the Business Combination and any Units that may be issued upon conversion of the Working Capital Loans (and their underlying securities) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of the IPO requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to Class A common stock). The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

Underwriting Agreement

 

The Company had granted the Underwriters a 30-day option from the date of IPO to purchase up to 1,800,000 additional Units to cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions.

 

Simultaneously upon the closing of the IPO, the Underwriters exercised the over-allotment option in full. As such, the Underwriters were paid an underwriting discount and commission of $0.20 per Unit, or $2,760,000 in the aggregate payable upon the closing of the IPO, and I-Bankers was entitled to a business combination marketing fee of $4,830,000 in the aggregate, which is held in the Trust Account and payable upon completion of the Business Combination.

 

NOTE 7 — PROMISSORY NOTE

 

On December 5, 2022, the company issued an unsecured promissory note (the “Note”) in the principal amount of $1,380,000 to Chijet. Chijet, entered into a business combination agreement with the Company, among others, on October 25, 2022. The Note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.

 

On March 6, 2023, the company issued an unsecured promissory note in the principal amount of $1,180,000 to Chijet. The Note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.

 

On March 6, 2023, the Company issued an unsecured promissory note in the principal amount of $100,000 to Jupiter Wellness Investment Corp., a wholly owned subsidiary of Jupiter Wellness, Inc. The Note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.

 

On March 8, 2023, the Company issued an unsecured promissory note in the principal amount of $200,000 to Jupiter Wellness, Inc. This note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.

 

14

 

 

NOTE 8 — STOCKHOLDERS’ EQUITY

 

The Company is authorized to issue a total of 111,000,000 shares, par value of $0.0001 per share, consisting of (a) 110,000,000 shares of common stock, including (i) 100,000,000 shares of Class A common stock, and (ii) 10,000,000 shares of Class B common stock, and (b) 1,000,000 shares of preferred stock (the “Preferred Stock”).

 

As of March 31, 2023 and September 30, 2022, there were 905,000 shares of Class A common stock and 3,450,000 shares of Class B common stock issued and outstanding, which such amount having been restated to reflect a 0.2 for 1 stock dividend for each share of Class B common stock outstanding in December 2021 (excluding 13,800,000 shares of Class A common stock subject to possible redemption).

 

Of the 3,450,000 shares of Class B common stock outstanding, an aggregate of up to 450,000 shares of Class B common stock were subject to forfeiture, to the extent that the underwriters’ over-allotment option is not exercised in full or in part, so that the Sponsor would collectively own 20% of the Company’s issued and outstanding common stock after the IPO (assuming Sponsor does not purchase any Public Shares in the IPO). As a result of the Underwriters’ full exercise of the over-allotment option on December 9, 2021, no share of Class B common stock is subject to forfeiture.

 

As of March 31, 2023 and September 30, 2022, no share of Preferred Stock was issued or outstanding. The designations, voting and other rights and preferences of the Preferred Stock may be determined from time to time by the Company’s board of directors.

 

Rights

 

Each holder of a right will receive one-eighth (1/8) of one share of Class A common stock upon consummation of a Business Combination. In the event the Company will not be the surviving entity upon completion of the Company’s initial Business Combination, each holder of a public right will automatically receive the 1/8 share of Class A common stock underlying such public right (without paying any additional consideration); and each holder of a Private Placement Right or right underlying Units to be issued upon conversion of the Working Capital Loans will be required to affirmatively convert its rights in order to receive the 1/8 share of Class A common stock underlying each right (without paying any additional consideration). If the Company is unable to complete an initial Business Combination within the required time period and public stockholders redeem the public shares for the funds held in the Trust Account, holders of rights will not receive any such funds in exchange for their rights and the rights will expire worthless. The Company will not issue fractional shares upon conversion of the rights. If, upon conversion of the rights, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exchange, comply with Section 155 of the Delaware General Corporation Law. The Company will make the determination of how to treat fractional shares at the time of its initial Business Combination and will include such determination in the proxy materials that it will send to stockholders for their consideration of such initial Business Combination.

 

If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure to deliver securities to the holders of the rights upon consummation of a Business Combination. Additionally, in no event will the Company be required to net cash settle the rights. Accordingly, the rights may expire worthless.

 

Representative Warrants and Representative Shares

 

Upon the closing of the IPO, the Company issued to the Underwriters Representative Warrants, the exercise price of which will be $12.00 per Share, and 276,000 Representative Shares.

 

The Representative Warrants shall be exercisable, in whole or in part, commencing the later of December 9, 2022 and the closing of the Company’s initial Business Combination and terminating on December 9, 2026.

 

15

 

 

The Company accounted for the 414,000 warrants as an expense of the IPO resulting in a charge directly to stockholders’ equity. The fair value of Representative Warrants was estimated to be approximately $1,087,164 (or $2.626 per warrant) using the Black-Scholes option-pricing model. The fair value of the Representative Warrants granted to the Underwriters was estimated as of the date of grant using the following assumptions: (1) expected volatility of 35%, (2) risk-free interest rate of 1.18% and (3) expected life of five years. The Representative Warrants and the shares of Class A common stock underlying Representative Warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up immediately following December 9, 2021 pursuant to FINRA Rule 511€)(1). The Representative

 

Warrants grants to holders demand and “piggy back” rights for periods of five and seven years from December 9, 2021. The Company will bear all fees and expenses attendant to registering the securities, other than underwriting commissions which will be paid for by the holders themselves. The exercise price and number of shares issuable upon exercise of the Representative Warrants may be adjusted in certain circumstances including in the event of a stock dividend, or the Company’s recapitalization, reorganization, merger or consolidation. However, the Representative Warrants will not be adjusted for issuances of Class A common stock at a price below its exercise price.

 

The Underwriters agreed not to transfer, assign or sell any of the Representative Shares without the Company’s prior written consent until the completion of the Business Combination. The Underwriters agreed (i) to waive its redemption rights with respect to such shares in connection with the completion of the initial Business Combination and (ii) to waive its rights to liquidating distributions from the Trust Account with respect to the Representative Shares if the Company fails to complete its initial Business Combination within Combination Period. The shares have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following December 9, 2021 pursuant to FINRA Rule 5110(e)(1).

 

NOTE 9 — SUBSEQUENT EVENTS

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statement was available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statement.

 

16

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Jupiter Wellness Acquisition Corp. References to our “management” or our “management team” refer to our officers and directors, and references to the “Sponsor” refer to Jupiter Wellness Sponsor LLC. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report.

 

Special Note Regarding Forward-Looking Statements

 

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Exchange Act that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s final prospectus for its initial public offering filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

 

Overview

 

We are a blank check company formed under the laws of the State of Delaware on September 14, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses. We intend to effectuate our business combination using cash from the proceeds of the initial public offering and the sale of the private units, our capital stock, debt or a combination of cash, stock and debt.

 

All activity through March 31, 2023, relates to our formation, initial public offering, and search for a prospective Initial Business Combination.

 

Results of Operations

 

We have neither engaged in any operations nor generated any revenues to date. Our only activities from inception through March 31, 2023, were organizational activities and those necessary to prepare for the initial public offering, described below, and searching for a prospective Initial Business Combination. We do not expect to generate any operating revenues until after the completion of our Initial Business Combination. We expect to generate non-operating income in the form of interest income on marketable securities held after the initial public offering. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses related to our search for targets for our Initial Business Combination.

 

For the six months ended March 31, 2023, we had a net income of $763,257, which consisted of operating costs of $1,391,207 and net other income of $2,700,587.

 

For the six months ended March 31, 2022, we had a net loss of $378,001, which consisted of operating costs of $365,156 and net other loss of $12,845.

 

17

 

 

Liquidity and Capital Resources

 

On December 9, 2021, we consummated the initial public offering of 13,800,000 units, which included the full exercise of the underwriter’s option to purchase up to an additional 1,800,000 units at the initial public offering price to cover over-allotments, at a price of $10.00 per unit, generating gross proceeds of $138,000,000. Simultaneously with the closing of the initial public offering, we consummated the sale of 629,000 placement units at a price of $10.00 per placement unit in a private placement to the Sponsor and I-Bankers Securities, Inc., generating gross proceeds of $6,290,000.

 

Following the initial public offering and the private placement, a total of $139,380,000 was placed in the trust account. We incurred $7,985,917 consisting of $2,760,000 in cash of underwriting commissions, $4,830,000 of business combination marketing fee, and $395,917 of other offering costs.

 

As of March 31, 2023, we had marketable securities held in the Trust Account of $145,433,953 consisting of Open-end Non-sweep Money Market Funds.

 

We had $17,731 of cash held outside of the Trust Account as of March 31, 2023. The Company did not have any cash equivalents as of March 31, 2023.

 

We intend to use substantially all of the funds held in the trust account, including any amounts representing interest earned on the trust account to complete our business combination. We may withdraw interest to pay taxes. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our business combination, the remaining proceeds held in the trust account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

 

We intend to use the funds held outside the trust account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a business combination.

 

In order to fund working capital deficiencies or finance transaction costs in connection with a business combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete a business combination, we may repay such loaned amounts out of the proceeds of the trust account released to us. In the event that a business combination does not close, we may use a portion of the working capital held outside the trust account to repay such loaned amounts, but no proceeds from our trust account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into units, at a price of $10.00 per unit, at the option of the lender. The units would be identical to the placement units.

 

We anticipate that the $17,731 outside of the Trust account as of March 31, 2023 will not be sufficient to allow us to operate for at least the next 12 months, assuming that a Business Combination is not consummated during that time. Moreover, we may need to obtain additional financing to consummate our Initial Business Combination but there is no assurance that new financing will be available to us on commercially acceptable terms. Furthermore, if we are not able to consummate a Business Combination by March 9, 2023, it will trigger our automatic winding up, liquidation and dissolution. We may extend the Combination Period by up to three months if the Sponsor deposits $1,380,000 into our Trust Account for three-month extension but there is no assurance that the Sponsor will do so. These conditions raise substantial doubt about our ability to continue as a going concern.

 

Critical Accounting Policies and Estimates

 

The preparation of the unaudited financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited financial statements and the reported amounts of expenses during the reporting period. We don’t believe there are any critical accounting policies or estimates.

 

Off-Balance Sheet Arrangements

 

We did not have any off-balance sheet arrangements as of March 31, 2023.

 

18

 

 

Common Stock Subject to Possible Redemption

 

All of the 13,800,000 shares of Class A common stock sold as part of the Units in the IPO contain a redemption feature. In accordance with the Accounting Standards Codification 480-10-S99-3A “Classification and Measurement of Redeemable Securities”, redemption provisions not solely within the control of the Company require the security to be classified outside of permanent equity. Ordinary liquidation events, which involve the redemption and liquidation of all of the entity’s equity instruments, are excluded from the provisions of ASC 480. The change in the carrying value of redeemable shares of common stock resulted in charges against additional paid-in capital and accumulated deficit. Accordingly, at March 31, 2023, the shares of Class A common stock subject to possible redemption in the amount of $144,837,830 were presented as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.

 

Contractual Obligations

 

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than described below.

 

We have engaged I-Bankers Securities, Inc. as an advisor in connection with our business combination to assist us in holding meetings with our stockholders to discuss the potential business combination and the target business’ attributes, introduce us to potential investors that are interested in purchasing our securities in connection with our initial business combination, assist us in obtaining stockholder approval for the business combination and assist us with our press releases and public filings in connection with the business combination. We will pay I-Bankers Securities, Inc. a cash fee of $4,830,000 for such services upon the consummation of our initial business combination (exclusive of any applicable finders’ fees which might become payable).

 

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the period reported. Actual results could materially differ from those estimates. We have not identified any critical accounting policies.

 

Recent Accounting Standards

 

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our financial statements.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not required for smaller reporting companies.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended March 31, 2023, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial and accounting officer have concluded that, during the period covered by this report, our disclosure controls and procedures were not effective.

 

Changes in Internal Control over Financial Reporting

 

During the most recently completed fiscal quarter ended March 31, 2023, there have been no changes in our internal controls over financial reporting that has materially affected, or is reasonably likely to affect, our internal control over financial reporting.

 

19

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

None.

 

Item 1A. Risk Factors.

 

Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our registration statements on Form S-1 (Nos. 333-260667 and 333-261513) and our Quarterly Report on Form 10-Q for the period ended March 31, 2023. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in our Registration Statements or our Quarterly Report on Form 10-Q for the period ended March 31, 2023, except we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

We did not issue any unregistered equity securities during the six months ended March 31, 2023.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not Applicable.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits

 

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

 

No.   Description of Exhibit
31.1*   Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

* Filed herewith.
   
** Furnished herewith.

 

20

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  JUPITER WELLNESS ACQUISITION CORP.
     
Date: May 19, 2023 By: /s/ Brian S. John
  Name: Brian S. John
  Title: Chief Executive Officer
    (Principal Executive Officer)
     
Date: May 19, 2023 By: /s/ Ke Li
  Name: Ke Li
  Title: Chief Financial Officer
    (Principal Accounting and Financial Officer)

 

21

 EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION

PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Brian S. John, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Jupiter Wellness Acquisition Corp.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: May 19, 2023 By: /s/ Brian S. John
    Brian S. John
    Chief Executive Officer (Principal Executive Officer)

 

 

 EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION

PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Ke Li, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Jupiter Wellness Acquisition Corp.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: May 19, 2023 By: /s/ Ke Li
  Name: Ke Li
  Title: Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

 EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Jupiter Wellness Acquisition Corp. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian S. John, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 19, 2023

 

  /s/ Brian S. John
  Name: Brian S. John
  Title: Chief Executive Officer
    (Principal Executive Officer)

 

 

 EX-32.2 5 ex32-2.htm

 

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Jupiter Wellness Acquisition Corp. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ke Li, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 19, 2023

 

  /s/ Ke Li
  Name: Ke Li
  Title: Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

 

 

 EX-101.SCH 6 jwac-20230331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Changes in Stockholders' (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Changes in Stockholders' (Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - ORGANIZATION AND BUSINESS OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Public Offering link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - BUSINESS COMBINATION link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - PROMISSORY NOTE link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - ORGANIZATION AND BUSINESS OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Public Offering (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - BUSINESS COMBINATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - PROMISSORY NOTE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 jwac-20230331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 jwac-20230331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 jwac-20230331_lab.xml XBRL LABEL FILE Class of Stock [Axis] Class A common stock, par value $0.0001 per share Rights, exchangeable for one-eighth of one share of Class A common stock Common Class A [Member] Common Class B [Member] Related and Nonrelated Party Status [Axis] Related Party [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Sale of Stock [Axis] IPO [Member] Over-Allotment Option [Member] Business Acquisition [Axis] Post Transaction [Member] Legal Entity [Axis] American Stock Transfer & Trust Company, LLC [Member] Title of Individual [Axis] Seller [Member] Earnout Participants [Member] Chijet Motor Company Inc [Member] Jupiter Wellness Acquisition Corp [Member] Scenario [Axis] Forecast [Member] Private Placement [Member] Chief Financial Officer [Member] Management and Directors [Member] Debt Instrument [Axis] Unsecured Promissory Note [Member] Jupiter Wellness Investment Corp [Member] Directors and Officers [Member] Class of Warrant or Right [Axis] Representative Warrants [Member] Measurement Input Type [Axis] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Term [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Assets Current assets Cash Prepaid expense Cash and marketable securities held in Trust Account Total current assets Total assets Liabilities and Stockholders’ (Deficit) Current Liabilities Accrued expense-related party Accrued expense Franchise tax Payable Income tax Payable Deferred underwriting fee Promissory Note - related party Extension loan Total current liabilities Total liabilities Commitments Common stock subject to possible redemption Stockholders’ (Deficit) Preferred stock, $0.0001 par value, 1,000,000 shares authorized, -0- shares issued and outstanding Common stock value Additional paid in capital Accumulated (deficits) Total Stockholders’ (Deficit) Total Liabilities and Stockholders’ (Deficit) Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Operating expense Officers compensation Franchise Tax General and administrative expenses Total operating expense Other Income/(Expense), net Net Income (loss) before income tax Income Tax Net Income (loss) Net income (loss) per share: Weighted average shares outstanding, basic and dilutive Weighted average shares outstanding, basic and dilutive shares Basic and diluted net income (loss) per share Basic and diluted net loss per share Balance Balance, shares Sale of 13,800,000 Units at IPO Sale of 13,800,000 Units at IPO, shares Offering Cost-Funds Flow Class A units issued for Representative shares Class A units issued for Representative shares, shares Deferred underwriting fee Sale of 629,000 private units Sale of 629,000 private units, shares Common stock subject to possible redemption Common stock subject to possible redemption, shares Reclassification from negative additional paid-in capital to accumulated deficit Net loss Additional amount deposited into trust Accretion for Class A common stock to redemption amount Balance Balance, shares Statement of Stockholders' Equity [Abstract] Sale of Units at IPO, shares Sale of private units, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Income (loss) Adjustments to reconcile net income to net cash Interest earned on marketable securities held in Trust Account Unrealized loss from the trust account Changes in operating assets and liabilities: Franchise tax payable Income tax payable Prepaid expense Accrued expense-related party Accrued expense Net cash (used in) operating activities Cash flows from investing activities: Investment of cash in Trust Account Net cash (used in) financing activities Cash flows from financing activities: Proceeds from sale of Units, net of underwriting discounts and offering expenses paid Proceeds from sale of private units Proceeds from note payable Proceeds (Repayment) to notes payable - related parties Net cash provided by financing activities Net increase/(decrease) in cash and cash equivalents Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest Cash paid for income taxes Non-Cash investing and financing activities: Funds attributable to common stock subject to redemption Initial classification of ordinary shares subject to possible redemption Deferred Underwriting Fee Accretion for Class A common stock to redemption amount Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND BUSINESS OPERATIONS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Public Offering Public Offering Business Combination and Asset Acquisition [Abstract] BUSINESS COMBINATION Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Promissory Note PROMISSORY NOTE Equity [Abstract] STOCKHOLDERS’ EQUITY Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Emerging Growth Company Status Use of Estimates Cash and Cash Equivalents Marketable Securities Held in Trust Account Offering Costs Associated with the IPO Class A Common Stock Subject to Possible Redemption Concentration of Credit Risk Fair Value of Financial Instruments Business Combination Marketing Fee Stock-Based Compensation Income Taxes Warrants Recent Accounting Pronouncements IPO Units Private placement equivalent units price IPO Units Private placement units Generating gross proceeds Transaction costs Underwriting discount and commission aggregate payable Business combination marketing fee Other offering costs Banking regulation, total capital, actual Fair market value of net assets Post transaction ownership Company net proceeds of IPO and private placement sale Price per unit sold Business combination net tangible assets Company obligation to redeem Interest to pay dissolution expenses IPO listing price IPO listing units Percentage of over-allotment units Stock issued during period, shares, new issues Underwriting commissions Percentage of gross proceeds raised for services Shares of Class A to purchase Representative Warrants percent Warrants price per share Representative shares Gross proceeds of the IPO Assets held in trust current Underwriting discount and commission aggregate payable Offering cost stockholders equity Offering costs current liabilities IPO shares Common stock subject to possible redemption amount Federal depositoryh insurance amount Income taxes Sale of units at IPO Sale of stock units Proceeds from issuance of public offering Sale of stock, description Stock held in trust Principal amount Deposits into trust account Deposits into trust account Proceeds from trust account Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Shares purchased during period Shares purchased during period, value Stock split description Shares issued as split stock Shares issued as forfeited Shares issued and outstanding percent Proceeds from issuance of private placement Accrued expense related party Working capital loans Sales units price per share Working capital loans outstanding Debt principle amount Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Ccommon stock issuable, shares Shares purchase grant option Underwriting price per unit Underwriting expense payment Marketing fees Debt Instrument, Face Amount Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Shares authorized Share price per share Common stock subject to redemption Common stock, shares outstanding Preferred stock issued Preferred stock outstanding Common stock, terms of conversion Warrants to purchase shares Representative warrants Fair value of representative warrants Warrant measurement inputs Warrant measurement inputs Rights, exchangeable for one-eighth of one share of Class A common stock. Class A common stock, par value $0.0001 per share. Deferred underwriting fee current. Increase decrease in accrued expenses related party. Deferred underwriting fee. Non Cash Accretion For Class Common Stock To Redemption Amount Post Transaction [Member] American Stock Transfer & Trust Company, LLC [Member] Business combination net tangible assets. Listing amount. Listing units. Over allotment units. Gross proceeds for services. Percentage of warrants issued. Representative shares. Emerging Growth Company Status [PolicyTextBlock] Offering Costs Associated With The Ipo [PolicyTextBlock] Class A Common Stock Subject To Possible Redemption [PolicyTextBlock] Warrants [PolicyTextBlock] Public Offering [Text Block] Seller [Member] Earnout Participants [Member] Chijet Motor Company Inc [Member] Shares issued and outstanding percent. Management and Directors [Member] Working capital loans. Working Capital Loans Outstanding Shares to be issued during period. Directors and Officers [Member] Underwriting price per unit. Promissory Note [Text Block] Jupiter Wellness Investment Corp [Member] Jupiter Wellness Acquisition Corp [Member] Representative Warrants [Member] Partners Capital Account Public Sale Of Units Shares Stock Issued During Period Value Common Stock Subject To Possible Redemption Stock Issued During Period Value Common Stock Subject To Possible Redemption Shares Stock Issued During Period Value Accretion For Common Stock To Redemption Amount Accrued expense related party. Franchise tax payable. Income tax payable current. Franchise tax. Additional amount deposited into trust. Increase decrease in accrued franchise taxes payable. Unsecured Promissory Note [Member] Funds attributable to common stock subject to redemption. Assets, Current Assets [Default Label] Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Adjustments to Additional Paid in Capital, Other StockIssuedDuringPeriodValueCommonStockSubjectToPossibleRedemption Marketable Securities, Gain (Loss) Unrealized Gain (Loss) on Investments Increase (Decrease) in Prepaid Expense IncreaseDecreaseInAccruedExpensesRelatedParty Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Trust Preferred Investments Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations NonCashAccretionForClassCommonStockToRedemptionAmount PublicOfferingTextBlock Warrants and Rights Outstanding, Term EX-101.PRE 10 jwac-20230331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
 6 Months Ended
Mar. 31, 2023
May 19, 2023
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2023  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --09-30  
Entity File Number 001-41126  
Entity Registrant Name JUPITER WELLNESS ACQUISITION CORP.  
Entity Central Index Key 0001883799  
Entity Tax Identification Number 87-2646504  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 1061 E. Indiantown Road  
Entity Address, Address Line Two Suite 110  
Entity Address, City or Town Jupiter  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33477  
City Area Code 561  
Local Phone Number 244-7100  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company true  
Class A common stock, par value $0.0001 per share    
Title of 12(b) Security Class A common stock, par value $0.0001 per share  
Trading Symbol JWAC  
Security Exchange Name NASDAQ  
Rights, exchangeable for one-eighth of one share of Class A common stock    
Title of 12(b) Security Rights, exchangeable for one-eighth of one share of Class A common stock  
Trading Symbol JWACR  
Security Exchange Name NASDAQ  
Common Class A [Member]    
Entity Common Stock, Shares Outstanding   14,705,000
Common Class B [Member]    
Entity Common Stock, Shares Outstanding   3,450,000
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheets - USD ($)
Mar. 31, 2023
Sep. 30, 2022
Current assets    
Cash $ 17,731 $ 610,382
Prepaid expense 112,529 251,085
Cash and marketable securities held in Trust Account 145,433,953 140,173,416
Total current assets 145,564,213 141,034,883
Total assets 145,564,213 141,034,883
Current Liabilities    
Accrued expense 145,000 40,000
Franchise tax Payable 50,000
Income tax Payable 546,123
Deferred underwriting fee 4,830,000 4,830,000
Promissory Note - related party 300,000
Extension loan 2,560,000
Total current liabilities 8,444,790 4,878,667
Total liabilities 8,444,790 4,878,667
Common stock subject to possible redemption 144,837,830 139,973,416
Stockholders’ (Deficit)    
Preferred stock, $0.0001 par value, 1,000,000 shares authorized, -0- shares issued and outstanding
Additional paid in capital
Accumulated (deficits) (7,718,843) (3,817,636)
Total Stockholders’ (Deficit) (7,718,407) (3,817,200)
Total Liabilities and Stockholders’ (Deficit) 145,564,213 141,034,883
Common Class A [Member]    
Stockholders’ (Deficit)    
Common stock value 91 91
Common Class B [Member]    
Stockholders’ (Deficit)    
Common stock value 345 345
Related Party [Member]    
Current Liabilities    
Accrued expense-related party $ 13,667 $ 8,667
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2023
Sep. 30, 2022
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common Class A [Member]    
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 905,000 905,000
Common stock, shares outstanding 905,000 905,000
Common Class B [Member]    
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 10,000,000 10,000,000
Common stock, shares issued 3,450,000 3,450,000
Common stock, shares outstanding 3,450,000 3,450,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Operations - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Operating expense        
Officers compensation $ 15,000 $ 8,667 $ 30,000 $ 18,667
Franchise Tax 50,000 100,000
General and administrative expenses 1,155,037 230,366 1,261,207 346,489
Total operating expense 1,220,037 239,033 1,391,207 365,156
Other Income/(Expense), net 1,518,128 (13,391) 2,700,587 (12,845)
Net Income (loss) before income tax 298,091 (252,424) 1,309,380 (378,001)
Income Tax (308,307) (546,123)
Net Income (loss) $ (10,216) $ (252,424) $ 763,257 $ (378,001)
Common Class A [Member]        
Weighted average shares outstanding, basic and dilutive        
Weighted average shares outstanding, basic and dilutive shares 14,705,000 14,705,000 14,705,000 9,049,231
Basic and diluted net income (loss) per share        
Basic and diluted net loss per share $ (0.00) $ (0.01) $ 0.04 $ (0.03)
Common Class B [Member]        
Weighted average shares outstanding, basic and dilutive        
Weighted average shares outstanding, basic and dilutive shares 3,450,000 3,450,000 3,450,000 3,238,324
Basic and diluted net income (loss) per share        
Basic and diluted net loss per share $ (0.00) $ (0.01) $ 0.04 $ (0.03)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Changes in Stockholders' (Deficit) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Common Class A [Member]
Common Stock [Member]
Common Class B [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Sep. 30, 2021 $ 345 $ 49,655 $ (21,015) $ 28,985
Balance, shares at Sep. 30, 2021 3,450,000      
Sale of 13,800,000 Units at IPO $ 1,380 137,998,620 138,000,000
Sale of 13,800,000 Units at IPO, shares   13,800,000        
Offering Cost-Funds Flow (3,155,917) (3,155,917)
Class A units issued for Representative shares $ 28 (28)
Class A units issued for Representative shares, shares   276,000        
Deferred underwriting fee (4,830,000) (4,830,000)
Sale of 629,000 private units $ 63 6,289,937 $ 6,290,000
Sale of 629,000 private units, shares   629,000       629,000
Common stock subject to possible redemption $ (1,380) (139,378,620) $ (139,380,000)
Common stock subject to possible redemption, shares   (13,800,000)        
Reclassification from negative additional paid-in capital to accumulated deficit 3,026,353 (3,026,353)
Net loss (125,577) (125,577)
Balance at Dec. 31, 2021 $ 91 $ 345 (3,172,945) (3,172,509)
Balance, shares at Dec. 31, 2021 905,000 3,450,000      
Balance at Sep. 30, 2021 $ 345 49,655 (21,015) 28,985
Balance, shares at Sep. 30, 2021 3,450,000      
Net loss           (378,001)
Balance at Mar. 31, 2022 $ 91 $ 345 (3,425,369) (3,424,933)
Balance, shares at Mar. 31, 2022 905,000 3,450,000      
Balance at Dec. 31, 2021 $ 91 $ 345 (3,172,945) (3,172,509)
Balance, shares at Dec. 31, 2021 905,000 3,450,000      
Net loss (252,424) (252,424)
Balance at Mar. 31, 2022 $ 91 $ 345 (3,425,369) (3,424,933)
Balance, shares at Mar. 31, 2022 905,000 3,450,000      
Balance at Sep. 30, 2022 $ 91 $ 345 (3,817,636) (3,817,200)
Balance, shares at Sep. 30, 2022 905,000 3,450,000      
Net loss 773,473 773,473
Additional amount deposited into trust (1,380,000) (1,380,000)
Accretion for Class A common stock to redemption amount (1,182,459) (1,182,459)
Balance at Dec. 31, 2022 $ 91 $ 345 (5,606,622) (5,606,186)
Balance, shares at Dec. 31, 2022 905,000 3,450,000      
Balance at Sep. 30, 2022 $ 91 $ 345 (3,817,636) (3,817,200)
Balance, shares at Sep. 30, 2022 905,000 3,450,000      
Offering Cost-Funds Flow           (3,155,917)
Net loss           763,257
Balance at Mar. 31, 2023 $ 91 $ 345 (7,718,843) (7,718,407)
Balance, shares at Mar. 31, 2023 905,000 3,450,000      
Balance at Dec. 31, 2022 $ 91 $ 345 (5,606,622) (5,606,186)
Balance, shares at Dec. 31, 2022 905,000 3,450,000      
Net loss (10,216) (10,216)
Additional amount deposited into trust (1,180,000) (1,180,000)
Accretion for Class A common stock to redemption amount (922,005) (922,005)
Balance at Mar. 31, 2023 $ 91 $ 345 $ (7,718,843) $ (7,718,407)
Balance, shares at Mar. 31, 2023 905,000 3,450,000      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Changes in Stockholders' (Deficit) (Parenthetical) - shares
 3 Months Ended
Dec. 09, 2021
Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]    
Sale of Units at IPO, shares   13,800,000
Sale of private units, shares 629,000 629,000
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Cash Flows - USD ($)
 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net Income (loss) $ 763,257 $ (378,001)
Adjustments to reconcile net income to net cash    
Interest earned on marketable securities held in Trust Account (2,700,587) (13,952)
Unrealized loss from the trust account 26,797
Changes in operating assets and liabilities:    
Franchise tax payable 50,000
Income tax payable 546,123
Prepaid expense 138,556 (253,119)
Accrued expense-related party 5,000 18,667
Accrued expense 105,000 99,687
Net cash (used in) operating activities (1,092,651) (499,921)
Cash flows from investing activities:    
Investment of cash in Trust Account (2,360,000) (139,380,000)
Net cash (used in) financing activities (2,360,000) (139,380,000)
Cash flows from financing activities:    
Proceeds from sale of Units, net of underwriting discounts and offering expenses paid 134,844,083
Proceeds from sale of private units 6,290,000
Proceeds from note payable 2,560,000
Proceeds (Repayment) to notes payable - related parties 300,000 (371,650)
Net cash provided by financing activities 2,860,000 140,762,433
Net increase/(decrease) in cash and cash equivalents (592,651) 882,512
Cash and cash equivalents at the beginning of the period 610,382 363,135
Cash and cash equivalents at the end of the period 17,731 1,245,647
SUPPLEMENTAL CASH FLOW INFORMATION:    
Cash paid for interest
Cash paid for income taxes
Non-Cash investing and financing activities:    
Funds attributable to common stock subject to redemption 2,560,000
Initial classification of ordinary shares subject to possible redemption 139,380,000
Deferred Underwriting Fee 4,830,000
Accretion for Class A common stock to redemption amount $ 2,104,464
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND BUSINESS OPERATIONS
 6 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND BUSINESS OPERATIONS

Note 1 — ORGANIZATION AND BUSINESS OPERATIONS

 

Jupiter Wellness Acquisition Corporation (the “Company”) is a blank check company incorporated on September 14, 2021, under the laws of the State of Delaware for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (a “Business Combination”). On October 26, 2022, the Company identified a target company for a Business Combination and activities in connection with the proposed acquisition of Chijet Inc., a Cayman Islands exempted company (see Note 4). The Company will not generate any operating revenues until after consummation of the initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the IPO.

 

As of March 31, 2023, the Company had not yet commenced any operations. All activity as of March 31, 2023, relates to the Company’s formation and the initial Public Offering (as defined below). The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected September 30 as its fiscal year end.

 

On December 9, 2021, the Company consummated its IPO of 13,800,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units, the “Public Shares”) at $10.00 per unit, which included 1,800,000 Units issued pursuant to the full exercise by the Underwriters (as defined below) of their over-allotment option, and the private sale of an aggregate of 629,000 Units (the “Private Placement Units” and with respect to the shares of Class A common stock included in the Units, the “Private Placement Shares”) to its sponsor, Jupiter Wellness Sponsor LLC (the “Sponsor”) and I-Bankers Securities, Inc. (“I-Bankers”) at a purchase price of $10.00 per Private Placement Unit, generating gross proceeds of $6,290,000 to the Company that closed simultaneously with the closing of the IPO (see Note 3). The Company’s Units have been listed on the Nasdaq Global Market (“Nasdaq”).

 

Transaction costs amounted to $7,985,917 consisting of $2,760,000 in cash of underwriting commissions, $4,830,000 of business combination marketing fee, and $395,917 of other offering costs. In addition, as of December 9, 2021, cash of $1,630,676 was held outside of the Trust Account (as defined below) and is available for working capital purposes.

 

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete a Business Combination with one or more operating businesses or assets that together have an aggregate fair market value equal to at least 80% of the net assets held in the Trust Account (net of amounts disbursed to management for working capital purposes, if permitted, and excluding the amount of any deferred underwriting commissions) at the time of the Company’s signing a definitive agreement in connection with its initial Business Combination. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires an interest in the target business or assets sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”).

 

Upon the closing of the IPO on December 9, 2021, the Company deposited $139,380,000 ($10.10 per Unit) from the proceeds of the IPO and certain proceeds of the sales of Private Placement Units in the trust account (“Trust Account”), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below.

 

 

The Company will provide its stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account (initially $10.10 per share), calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The shares of Class A common stock will be recorded at redemption value and classified as temporary equity upon the completion of the IPO, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”

 

The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 upon such completion of a Business Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination.

 

If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to (i) waive its redemption rights with respect to their Private Placement Shares in connection with the completion of the Business Combination, (ii) waive its redemption rights with respect to their Private Placement Shares in connection with a stockholder vote to approve an amendment to the Company’s second amended and restated certificate of incorporation (a) to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares if the Company does not complete the Business Combination within the Combination Period (as defined below) or (b) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination activity and (iii) waive its rights to liquidating distributions from the Trust Account with respect to their Private Placement Shares if the Company fails to complete the Business Combination within the Combination Period. In addition, the Sponsor has agreed to vote any share it held in favor of the Business Combination.

 

Additionally, each public stockholder may elect to redeem its Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination.

 

Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s second amended and restated certificate of incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares without the Company’s prior written consent.

 

The Company will have until 12 months from the closing of the IPO (or 18 months from the closing of the IPO if the Company may extend the period of time to consummate a Business Combination) (the “Combination Period”) to complete a Business Combination. If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than 10 business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (less up to $50,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and requirements of other applicable law. On December 6, 2022, the Company extended the Combination Period until March 8, 2023. On March 6, 2023, the Company deposited another extension payment to extend the Combination Period until June 8, 2023.

 

The Sponsor has agreed to waive its liquidation rights with respect to the Founder Shares (as defined below) and Private Placement Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor acquires Public Shares in or after the IPO, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their business combination marketing fees (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the IPO price per Unit ($10.10).

 

 

The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a third party for services rendered or products sold to the Company, or by a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.10 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent auditors), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

 

Underwriting Agreement and Business Combination Marketing Agreement

 

The Company engaged I-Bankers as the representative of the underwriters (the “Underwriters”) in the IPO of the Company’s Class A common stock, par value of $0.0001 per share (“Shares”), for $120 million and the simultaneous listing on Nasdaq. Pursuant to that certain underwriting agreement, I-Bankers acted as the representative of the Underwriters of the IPO for 12,000,000 Units at $10.00 per unit, plus an over-allotment option equal to 15% of the number of Units offered, or 1,800,000 Units, which was exercised in full simultaneously upon the closing of the IPO. The Company paid I-Bankers underwriters’ commission of $2,760,000, equal to 2.0% of the gross proceeds raised in the IPO for such services upon the consummation of the IPO (exclusive of any applicable finders’ fees which might become payable).

 

Upon the closing of the IPO, the Company issued to I-Bankers a five-year warrant to purchase 414,000 Shares of Class A common stock, equal to 3.0% of the Shares issued in the IPO (“Representative Warrants”). The exercise price of Representative Warrants is $12.00 per Share. In addition, I-Bankers was issued 276,000 shares of Class A common stock upon the consummation of IPO (“Representative Shares”).

 

In addition, under a business combination marketing agreement, the Company has engaged I-Bankers as an advisor in connection with the Business Combination and will pay I-Bankers a cash fee for such marketing services upon the consummation of the Business Combination in an amount equal to, in the aggregate, 3.5% of the gross proceeds of the IPO, including any proceeds from the exercise of the underwriters’ over-allotment option. The fee will become payable to the Underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

 

Going Concern Consideration

 

The Company expects to incur significant costs in pursuit of its financing and acquisition plans. In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that if the Company is unsuccessful in consummating an initial business combination within the prescribed period of time from the closing of the IPO, the requirement that the Company cease all operations, redeem the public shares and thereafter liquidate and dissolve raises substantial doubt about the ability to continue as a going concern. The balance sheet does not include any adjustments that might result from the outcome of this uncertainty. Management has determined that the Company has funds that are sufficient to fund the working capital needs of the Company until the consummation of an initial business combination or the winding up of the Company as stipulated in the Company’s amended and restated memorandum of association. The accompanying financial statement has been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern.

 

 

Risks and Uncertainties

 

Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a target company, the specific impact is not readily determinable as of the date of this financial statement. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 6 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of US Securities and Exchange Commission (“SEC”).

 

Emerging Growth Company Status

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act and modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company had $17,731 in cash as of March 31, 2023. The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2023.

 

 

Marketable Securities Held in Trust Account

 

At March 31, 2023, substantially all of the assets held in the Trust Account were held in money market funds which are invested primarily in U.S. Treasury securities. All of the Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. At March 31, 2023, $145,433,953 was held in the Trust Account.

 

Offering Costs Associated with the IPO

 

The Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the IPO that were directly related to the IPO. The Company incurred offering costs amounting to $7,985,917 as a result of the IPO consisting of $2,760,000 in cash of underwriting commissions, $4,830,000 of business combination marketing fee, and $395,917 of other offering costs. As of March 31, 2023, offering costs in the aggregate of $3,155,917 have been charged to stockholders’ equity and $4,830,000 have been classified to current liabilities, respectively.

 

Class A Common Stock Subject to Possible Redemption

 

All of the 13,800,000 shares of Class A common stock sold as part of the Units in the IPO contain a redemption feature. In accordance with the Accounting Standards Codification 480-10-S99-3A “Classification and Measurement of Redeemable Securities”, redemption provisions not solely within the control of the Company require the security to be classified outside of permanent equity. Ordinary liquidation events, which involve the redemption and liquidation of all of the entity’s equity instruments, are excluded from the provisions of ASC 480. The change in the carrying value of redeemable shares of common stock resulted in charges against additional paid-in capital and accumulated deficit. Accordingly, at March 31, 2023, the shares of Class A common stock subject to possible redemption in the amount of $144,837,830 were presented as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the federal depository insurance coverage corporation limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 

Fair Value of Financial Instruments

 

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.

 

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 

  ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;
     
  ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
     
  ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

 

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

 

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.

 

Business Combination Marketing Fee

 

Pursuant to the business combination marketing agreement, the Company has engaged I-Bankers as an advisor in connection with the Business Combination and will pay I-Bankers a cash fee for such marketing services upon the consummation of the Business Combination in an amount equal to, in the aggregate, 3.5% of the gross proceeds of the IPO, including any proceeds from the full or partial exercise of the underwriters’ over-allotment option.

 

Stock-Based Compensation

 

The Company recognizes compensation costs to employees under FASB Accounting Standards Codification 718 “Compensation – Stock Compensation” (“ASC 718”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

 

On September 14, 2021, the inception date, the Company adopted Accounting Standards Update (“ASU”) No. 2018-07 “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation – Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned.

 

Income Taxes

 

The Company complies with the accounting and reporting requirements of FASB ASC, 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. There were no unrecognized tax benefits as of March 31, 2023 and September 30, 2022. Deferred tax assets were deemed to be de minimis as of March 31, 2023 and September 30, 2022.

 

FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at March 31, 2023 and September 30, 2022.

 

Income taxes was accrued for $546,123 and $308,307 for the six and three months ended March 31, 2023, respectively.

 

 

Warrants

 

ASC 480 requires a reporting entity to classify certain freestanding financial instruments as liabilities (or in some cases as assets). ASC 480-10-S99 addresses concerns raised by the SEC regarding the financial statement classification and measurement of securities subject to mandatory redemption requirements or whose redemption is outside the control of the issuer. If the stock subject to mandatory redemption provisions represents the only shares in the reporting entity, it must report instruments in the liabilities section of its statement of financial position. The stock subject must then describe them as shares subject to mandatory redemption, so as to distinguish the instruments from other financial statement liabilities. The Company concludes that the warrants to I-Bankers do not exhibit any of the above characteristics and, therefore, are outside the scope of ASC 480. The warrants were issued in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging — Contracts in Entity’s Own Equity. Such guidance provides that because the warrants meet the criteria for equity treatment.

 

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statement.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Public Offering
 6 Months Ended
Mar. 31, 2023
Public Offering  
Public Offering

NOTE 3 — Public Offering

 

At the IPO, the Company sold 13,800,000 Units at a purchase price of $10.00 per Unit, which included 1,800,000 Units issued pursuant to the full exercise by the Underwriters of their over-allotment option, generating gross proceeds to the Company of $138,000,000. Each Unit consists of one share of Class A common stock of the Company, par value $0.0001 per share (“Class A common stock”), and one right to receive one-eighth of one share of Class A common stock upon the consummation of the Company’s initial business combination (see Note 6).

 

A total of $139,380,000 of the net proceeds from the IPO and the sale of the Private Placement Units was placed in a U.S.-based Trust Account maintained by American Stock Transfer & Trust Company, LLC, acting as trustee.

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
BUSINESS COMBINATION
 6 Months Ended
Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
BUSINESS COMBINATION

NOTE 4 — BUSINESS COMBINATION

 

On October 26, 2022, Jupiter Wellness Acquisition Corp., a blank check, special purpose acquisition company incorporated as a Delaware corporation (the “Company”), issued a press release (the “Press Release”) announcing that the Company has entered into a definitive Business Combination Agreement (the “BCA”) on October 25, 2022, with Chijet Inc., a Cayman Islands exempted company (together with its subsidiaries, “Chijet”), each of the referenced holders of Chijet’s outstanding capital shares (collectively, the “Sellers”) and certain other parties formed in connection with the transactions contemplated by the BCA (the “Business Combination”), including Chijet Motor Company, Inc., a Cayman Islands exempted company and a wholly owned subsidiary of Chijet (“Pubco”). Chijet indirectly holds controlling interests in Shandong Baoya New Energy Vehicle Co., Ltd., a Chinese company (“Baoya”), which is a producer and manufacturer of electric vehicles and FAW Jilin Automobile Co., Ltd., a Chinese company (“FAW Jilin”), which manufactures and sells traditional fuel vehicles.

 

Subject to the terms and conditions of the BCA, Pubco will acquire all of the issued and outstanding shares of Chijet from the Sellers (“Purchased Shares”) in exchange for ordinary shares of Pubco and Chijet shall surrender for no consideration its shares in Pubco, such that Chijet becomes a wholly owned subsidiary of Pubco and the Sellers become shareholders of Pubco (the “Share Exchange”). Immediately thereafter, Merger Sub will merge with and into the Company, with the Company continuing as the surviving entity, as a result of which, (i) the Company shall become a wholly owned subsidiary of Pubco, and (ii) each issued and outstanding security of the Company immediately prior to the consummation of the Business Combination shall no longer be outstanding and shall automatically be cancelled, in exchange for the right of the holder thereof to receive a substantially equivalent security of Pubco (and with the holders of the Company’s publicly traded shares of Class A common stock, par value $0.0001 per share (“Company Class A Common Stock”), that do not redeem their shares also receiving one (1) contingent value right (“CVR,” as defined in the BCA) for each share of Company Class A Common Stock held).

 

 

Pursuant to the BCA, at the closing, Pubco shall issue and deliver to the Sellers an aggregate number of Pubco ordinary shares (the “Exchange Shares”) with an aggregate value equal to One Billion Six Hundred Million U.S. Dollars ($1,600,000,000), with each Pubco ordinary share valued at the redemption price, and with each Seller receiving its pro rata share of the applicable Exchange Shares based on the number of Purchased Shares owned by such Seller, divided by the total number of purchased shares owned by all Sellers. However, the issuance to certain of the Sellers (the “Earnout Participants”) of Exchange Shares having a value of Six Hundred and Seventy Four Million U.S. Dollars ($674,000,000), with each of such shares being valued at the redemption price (such Pubco ordinary shares, subject to equitable adjustment for share splits, share dividends, combinations, recapitalizations and the like after the closing, including to account for any equity securities into which such shares are exchanged or converted, and together with the earnings thereof, the “Earnout Shares”), and each of the Earnout Participants shall have the contingent right to receive a pro rata portion of such Earnout Shares and earnings thereon (such pro rata allocation based on the number of Purchased Shares owned by such Earnout Participant, divided by the total number of Purchased shares owned by all Earnout Participants) based on Pubco and its subsidiaries achieving certain financial performance metrics over for calendar years 2023, 2024 and 2025 or meeting certain stock price metrics from the closing until 30 trading days after the date on which Pubco files its annual report for the calendar year ended December 31, 2023, 2024 and 2025, respectively with the SEC. To the extent that any such Earnout Shares are not earned, they (along with income thereon) will be redistributed pro rata to the holders of CVRs.

 

On December 5, 2022, the company issued an unsecured promissory note (the “Note”) in the principal amount of $1,380,000 to Chijet (See Note 7 for further discussion.). In connection with the issuance of the Note, on December 5, 2022, the Company deposited an aggregate of $1,380,000 into the trust account of the Company for its public stockholders, which enables the Company to further extend the period of time it has to consummate its initial business combination by three months from December 8, 2022 to March 9, 2023 (the “Extension”). The Extension is the first of up to two three-month extensions permitted under the Company’s governing documents.

 

On March 6, 2023, Jupiter Wellness Acquisition Corp. (the “Company”) issued two unsecured promissory note (the “Note”) in the principal amount totaling of $1,280,000 to Chijet, Inc. In connection with the issuance of the Note, on March 6, 2023, the Company deposited an aggregate of $1,380,000 into the trust account of the Company for its public stockholders, which enables the Company to further extend the period of time it has to consummate its initial business combination by three months from March 9, 2022 to June 8, 2023 (the “Extension”). The Extension is the second of up to two three-month extensions permitted under the Company’s governing documents. The $100,000 balance of the $1,380,000 was funded by the Company itself out of funds available in its operating account.

 

The business combination was not closed as of March 31, 2023.

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS
 6 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 5 — RELATED PARTY TRANSACTIONS

 

Founder Shares

 

On September 20, 2021, the Sponsor purchased 2,875,000 shares of the Company’s Class B common stock (the “Founder Shares”) for an aggregate purchase price of $50,000.

 

In December 2021, the Company effected a 0.2 for 1 stock dividend for each share of Class B common stock outstanding (which has been accounted for as a stock split) of 575,000 shares of Class B common stock, which resulted in an aggregate of 3,450,000 shares of Class B common stock outstanding. All share and associated amounts have been retroactively restated to reflect the share dividend.

 

The Founder Shares include an aggregate of up to 450,000 shares of Class B common stock subject to forfeiture by the Sponsor to the extent that the underwriters’ over-allotment is not exercised in full or in part, so that the number of Founder Shares will collectively represent 20% of the Company’s issued and outstanding shares upon the completion of the IPO. On December 9, 2021, the Underwriter exercised the over-allotment option in full. As a result, no Founder Shares is subject to for forfeiture (see Note 3).

 

 

Private Placement

 

Concurrently with the closing of the IPO, the Sponsor and the Underwriters purchased an aggregate of 629,000 Private Placement Units, generating gross proceeds of $6,290,000 in aggregate in a private placement. Each Private Placement Unit will consist of one share of Class A common stock and one right. Each right underlying the Private Placement Unit (the “Private Placement Right”) will entitle the holder to receive one-eighth of one share of Class A common stock at the closing of a Business Combination. The proceeds from the sale of the Private Placement Units have been added to the net proceeds from the IPO held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Placements Units and all underlying securities will expire worthless.

 

The Private Placement Units (including the underlying Private Placement Rights, the Private Placement Shares and the shares of Class A common stock issuable upon conversion of the Private Placement Rights) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination (except as described under the section of the IPO prospectus entitled “Principal Stockholders — Restrictions on Transfers of Founder Shares and Private Placement Units”). Following such period, the Private Placement Units (including the underlying Private Placement Rights, the Private Placement Shares and the shares of Class A common stock issuable upon conversion of the Private Placement Rights) will be transferable, assignable or salable, except that the Private Placement Units will not trade.

 

Accrued Expenses - Related Parties

 

Pursuant to the executed Offer Letters, the Company agreed to pay the Company’s Chief Financial Officer $5,000 in cash per month starting from December 9, 2021. As of March 31, 2023 and September 30, 2022, the Company had accrued expenses – related parties in amount of $13,667 and $8,667 in connection with the accrued compensation to the Company’s management and directors, respectively.

 

Working Capital Loans

 

In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or certain of the Company’s officers and directors or their affiliates may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into private placement-equivalent units at a price of $10.00 per unit at the option of the lender. Such units would be identical to the Private Placement Units. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of March 31, 2023, no Working Capital Loans were outstanding.

 

Promissory Note - Related Party

 

On March 6, 2023, the Company issued an unsecured promissory note in the principal amount of $100,000 to Jupiter Wellness Investment Corp., a wholly owned subsidiary of Jupiter Wellness, Inc. The Note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.

 

On March 8, 2023, the Company issued an unsecured promissory note in the principal amount of $200,000 to Jupiter Wellness, Inc. This note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.

 

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 6 — COMMITMENTS AND CONTINGENCIES

 

Registration Rights

 

The holders of the Founder Shares, Private Placement Units (and their underlying securities), the Representative Shares, the Representative Warrants (and their underlying securities), the 300,000 shares of Class A common stock issuable to the Company’s directors and officers within 10 days following the Business Combination and any Units that may be issued upon conversion of the Working Capital Loans (and their underlying securities) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of the IPO requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to Class A common stock). The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

Underwriting Agreement

 

The Company had granted the Underwriters a 30-day option from the date of IPO to purchase up to 1,800,000 additional Units to cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions.

 

Simultaneously upon the closing of the IPO, the Underwriters exercised the over-allotment option in full. As such, the Underwriters were paid an underwriting discount and commission of $0.20 per Unit, or $2,760,000 in the aggregate payable upon the closing of the IPO, and I-Bankers was entitled to a business combination marketing fee of $4,830,000 in the aggregate, which is held in the Trust Account and payable upon completion of the Business Combination.

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
PROMISSORY NOTE
 6 Months Ended
Mar. 31, 2023
Promissory Note  
PROMISSORY NOTE

NOTE 7 — PROMISSORY NOTE

 

On December 5, 2022, the company issued an unsecured promissory note (the “Note”) in the principal amount of $1,380,000 to Chijet. Chijet, entered into a business combination agreement with the Company, among others, on October 25, 2022. The Note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.

 

On March 6, 2023, the company issued an unsecured promissory note in the principal amount of $1,180,000 to Chijet. The Note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.

 

On March 6, 2023, the Company issued an unsecured promissory note in the principal amount of $100,000 to Jupiter Wellness Investment Corp., a wholly owned subsidiary of Jupiter Wellness, Inc. The Note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.

 

On March 8, 2023, the Company issued an unsecured promissory note in the principal amount of $200,000 to Jupiter Wellness, Inc. This note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.

 

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY
 6 Months Ended
Mar. 31, 2023
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 8 — STOCKHOLDERS’ EQUITY

 

The Company is authorized to issue a total of 111,000,000 shares, par value of $0.0001 per share, consisting of (a) 110,000,000 shares of common stock, including (i) 100,000,000 shares of Class A common stock, and (ii) 10,000,000 shares of Class B common stock, and (b) 1,000,000 shares of preferred stock (the “Preferred Stock”).

 

As of March 31, 2023 and September 30, 2022, there were 905,000 shares of Class A common stock and 3,450,000 shares of Class B common stock issued and outstanding, which such amount having been restated to reflect a 0.2 for 1 stock dividend for each share of Class B common stock outstanding in December 2021 (excluding 13,800,000 shares of Class A common stock subject to possible redemption).

 

Of the 3,450,000 shares of Class B common stock outstanding, an aggregate of up to 450,000 shares of Class B common stock were subject to forfeiture, to the extent that the underwriters’ over-allotment option is not exercised in full or in part, so that the Sponsor would collectively own 20% of the Company’s issued and outstanding common stock after the IPO (assuming Sponsor does not purchase any Public Shares in the IPO). As a result of the Underwriters’ full exercise of the over-allotment option on December 9, 2021, no share of Class B common stock is subject to forfeiture.

 

As of March 31, 2023 and September 30, 2022, no share of Preferred Stock was issued or outstanding. The designations, voting and other rights and preferences of the Preferred Stock may be determined from time to time by the Company’s board of directors.

 

Rights

 

Each holder of a right will receive one-eighth (1/8) of one share of Class A common stock upon consummation of a Business Combination. In the event the Company will not be the surviving entity upon completion of the Company’s initial Business Combination, each holder of a public right will automatically receive the 1/8 share of Class A common stock underlying such public right (without paying any additional consideration); and each holder of a Private Placement Right or right underlying Units to be issued upon conversion of the Working Capital Loans will be required to affirmatively convert its rights in order to receive the 1/8 share of Class A common stock underlying each right (without paying any additional consideration). If the Company is unable to complete an initial Business Combination within the required time period and public stockholders redeem the public shares for the funds held in the Trust Account, holders of rights will not receive any such funds in exchange for their rights and the rights will expire worthless. The Company will not issue fractional shares upon conversion of the rights. If, upon conversion of the rights, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exchange, comply with Section 155 of the Delaware General Corporation Law. The Company will make the determination of how to treat fractional shares at the time of its initial Business Combination and will include such determination in the proxy materials that it will send to stockholders for their consideration of such initial Business Combination.

 

If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure to deliver securities to the holders of the rights upon consummation of a Business Combination. Additionally, in no event will the Company be required to net cash settle the rights. Accordingly, the rights may expire worthless.

 

Representative Warrants and Representative Shares

 

Upon the closing of the IPO, the Company issued to the Underwriters Representative Warrants, the exercise price of which will be $12.00 per Share, and 276,000 Representative Shares.

 

The Representative Warrants shall be exercisable, in whole or in part, commencing the later of December 9, 2022 and the closing of the Company’s initial Business Combination and terminating on December 9, 2026.

 

 

The Company accounted for the 414,000 warrants as an expense of the IPO resulting in a charge directly to stockholders’ equity. The fair value of Representative Warrants was estimated to be approximately $1,087,164 (or $2.626 per warrant) using the Black-Scholes option-pricing model. The fair value of the Representative Warrants granted to the Underwriters was estimated as of the date of grant using the following assumptions: (1) expected volatility of 35%, (2) risk-free interest rate of 1.18% and (3) expected life of five years. The Representative Warrants and the shares of Class A common stock underlying Representative Warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up immediately following December 9, 2021 pursuant to FINRA Rule 511€)(1). The Representative

 

Warrants grants to holders demand and “piggy back” rights for periods of five and seven years from December 9, 2021. The Company will bear all fees and expenses attendant to registering the securities, other than underwriting commissions which will be paid for by the holders themselves. The exercise price and number of shares issuable upon exercise of the Representative Warrants may be adjusted in certain circumstances including in the event of a stock dividend, or the Company’s recapitalization, reorganization, merger or consolidation. However, the Representative Warrants will not be adjusted for issuances of Class A common stock at a price below its exercise price.

 

The Underwriters agreed not to transfer, assign or sell any of the Representative Shares without the Company’s prior written consent until the completion of the Business Combination. The Underwriters agreed (i) to waive its redemption rights with respect to such shares in connection with the completion of the initial Business Combination and (ii) to waive its rights to liquidating distributions from the Trust Account with respect to the Representative Shares if the Company fails to complete its initial Business Combination within Combination Period. The shares have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following December 9, 2021 pursuant to FINRA Rule 5110(e)(1).

 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS
 6 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 9 — SUBSEQUENT EVENTS

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statement was available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statement.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 6 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of US Securities and Exchange Commission (“SEC”).

 
Emerging Growth Company Status

Emerging Growth Company Status

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act and modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company had $17,731 in cash as of March 31, 2023. The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2023.

 

 
Marketable Securities Held in Trust Account

Marketable Securities Held in Trust Account

 

At March 31, 2023, substantially all of the assets held in the Trust Account were held in money market funds which are invested primarily in U.S. Treasury securities. All of the Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. At March 31, 2023, $145,433,953 was held in the Trust Account.

 
Offering Costs Associated with the IPO

Offering Costs Associated with the IPO

 

The Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the IPO that were directly related to the IPO. The Company incurred offering costs amounting to $7,985,917 as a result of the IPO consisting of $2,760,000 in cash of underwriting commissions, $4,830,000 of business combination marketing fee, and $395,917 of other offering costs. As of March 31, 2023, offering costs in the aggregate of $3,155,917 have been charged to stockholders’ equity and $4,830,000 have been classified to current liabilities, respectively.

 
Class A Common Stock Subject to Possible Redemption

Class A Common Stock Subject to Possible Redemption

 

All of the 13,800,000 shares of Class A common stock sold as part of the Units in the IPO contain a redemption feature. In accordance with the Accounting Standards Codification 480-10-S99-3A “Classification and Measurement of Redeemable Securities”, redemption provisions not solely within the control of the Company require the security to be classified outside of permanent equity. Ordinary liquidation events, which involve the redemption and liquidation of all of the entity’s equity instruments, are excluded from the provisions of ASC 480. The change in the carrying value of redeemable shares of common stock resulted in charges against additional paid-in capital and accumulated deficit. Accordingly, at March 31, 2023, the shares of Class A common stock subject to possible redemption in the amount of $144,837,830 were presented as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.

 
Concentration of Credit Risk

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the federal depository insurance coverage corporation limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.

 

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 

  ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;
     
  ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
     
  ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

 

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

 

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.

 
Business Combination Marketing Fee

Business Combination Marketing Fee

 

Pursuant to the business combination marketing agreement, the Company has engaged I-Bankers as an advisor in connection with the Business Combination and will pay I-Bankers a cash fee for such marketing services upon the consummation of the Business Combination in an amount equal to, in the aggregate, 3.5% of the gross proceeds of the IPO, including any proceeds from the full or partial exercise of the underwriters’ over-allotment option.

 
Stock-Based Compensation

Stock-Based Compensation

 

The Company recognizes compensation costs to employees under FASB Accounting Standards Codification 718 “Compensation – Stock Compensation” (“ASC 718”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

 

On September 14, 2021, the inception date, the Company adopted Accounting Standards Update (“ASU”) No. 2018-07 “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation – Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned.

 
Income Taxes

Income Taxes

 

The Company complies with the accounting and reporting requirements of FASB ASC, 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. There were no unrecognized tax benefits as of March 31, 2023 and September 30, 2022. Deferred tax assets were deemed to be de minimis as of March 31, 2023 and September 30, 2022.

 

FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at March 31, 2023 and September 30, 2022.

 

Income taxes was accrued for $546,123 and $308,307 for the six and three months ended March 31, 2023, respectively.

 

 
Warrants

Warrants

 

ASC 480 requires a reporting entity to classify certain freestanding financial instruments as liabilities (or in some cases as assets). ASC 480-10-S99 addresses concerns raised by the SEC regarding the financial statement classification and measurement of securities subject to mandatory redemption requirements or whose redemption is outside the control of the issuer. If the stock subject to mandatory redemption provisions represents the only shares in the reporting entity, it must report instruments in the liabilities section of its statement of financial position. The stock subject must then describe them as shares subject to mandatory redemption, so as to distinguish the instruments from other financial statement liabilities. The Company concludes that the warrants to I-Bankers do not exhibit any of the above characteristics and, therefore, are outside the scope of ASC 480. The warrants were issued in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging — Contracts in Entity’s Own Equity. Such guidance provides that because the warrants meet the criteria for equity treatment.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statement.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND BUSINESS OPERATIONS (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Dec. 09, 2021
Sep. 20, 2021
Dec. 31, 2021
Mar. 31, 2023
Mar. 31, 2022
Dec. 05, 2022
Oct. 26, 2022
Sep. 30, 2022
IPO Units       13,800,000        
Private placement equivalent units price $ 10.00     $ 10.00        
IPO Units     13,800,000          
Private placement units 629,000   629,000          
Generating gross proceeds $ 6,290,000     $ 6,290,000      
Transaction costs 7,985,917              
Underwriting discount and commission aggregate payable 2,760,000              
Business combination marketing fee 4,830,000              
Other offering costs 395,917              
Banking regulation, total capital, actual $ 1,630,676              
Fair market value of net assets 80.00%              
Company net proceeds of IPO and private placement sale           $ 1,380,000    
Price per unit sold $ 10.10     $ 0.0001        
Business combination net tangible assets $ 5,000,001              
Company obligation to redeem 100.00%              
Interest to pay dissolution expenses $ 50,000              
Common stock, par value             $ 0.0001  
IPO listing price $ 120,000,000              
IPO listing units 12,000,000              
Percentage of over-allotment units 15.00%              
Stock issued during period, shares, new issues 1,800,000 2,875,000            
Underwriting commissions $ 2,760,000              
Percentage of gross proceeds raised for services 2.00%              
Shares of Class A to purchase 414,000              
Representative Warrants percent 3.00%              
Warrants price per share $ 12.00              
Representative shares 276,000              
Gross proceeds of the IPO 3.50%              
Common Class A [Member]                
Common stock, par value $ 0.0001     $ 0.0001       $ 0.0001
American Stock Transfer & Trust Company, LLC [Member]                
Company net proceeds of IPO and private placement sale $ 139,380,000              
Price per unit sold $ 10.10              
Post Transaction [Member]                
Post transaction ownership 50.00%              
IPO [Member]                
IPO Units 13,800,000              
Private placement equivalent units price $ 10.00              
IPO Units 13,800,000              
Shares of Class A to purchase 414,000              
Warrants price per share $ 12.00              
Over-Allotment Option [Member]                
IPO Units 1,800,000              
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Dec. 09, 2021
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2021
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2022
Cash   $ 17,731     $ 17,731   $ 610,382
Assets held in trust current   145,433,953     145,433,953   $ 140,173,416
Transaction costs $ 7,985,917            
Underwriting discount and commission aggregate payable 2,760,000            
Business combination marketing fee 4,830,000            
Other offering costs $ 395,917            
Offering cost stockholders equity       $ 3,155,917 3,155,917    
Offering costs current liabilities         $ 4,830,000    
IPO shares         13,800,000    
Federal depositoryh insurance amount   250,000     $ 250,000    
Gross proceeds of the IPO 3.50%            
Income taxes   308,307   546,123  
Common Class A [Member]              
Common stock subject to possible redemption amount   $ 144,837,830     $ 144,837,830    
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Public Offering (Details Narrative) - USD ($)
 3 Months Ended
Dec. 09, 2021
Dec. 31, 2021
Mar. 31, 2023
Oct. 26, 2022
Sep. 30, 2022
Sale of units at IPO   13,800,000      
Sale of stock units $ 10.00   $ 10.00    
Proceeds from issuance of public offering $ 138,000,000        
Sale of stock, description Each Unit consists of one share of Class A common stock of the Company, par value $0.0001 per share (“Class A common stock”), and one right to receive one-eighth of one share of Class A common stock upon the consummation of the Company’s initial business combination (see Note 6)        
Common stock, par value       $ 0.0001  
American Stock Transfer & Trust Company, LLC [Member]          
Stock held in trust $ 139,380,000        
Common Class A [Member]          
Common stock, par value $ 0.0001   $ 0.0001   $ 0.0001
IPO [Member]          
Sale of units at IPO 13,800,000        
Sale of stock units $ 10.00        
Over-Allotment Option [Member]          
Sale of units at IPO 1,800,000        
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
BUSINESS COMBINATION (Details Narrative) - USD ($)
 3 Months Ended
Jun. 08, 2023
Mar. 06, 2023
Dec. 05, 2022
Oct. 26, 2022
Common stock, par value       $ 0.0001
Deposits into trust account     $ 1,380,000  
Deposits into trust account   $ 1,380,000    
Forecast [Member]        
Deposits into trust account $ 1,380,000      
Proceeds from trust account $ 100,000      
Chijet Motor Company Inc [Member]        
Principal amount     $ 1,380,000  
Jupiter Wellness Acquisition Corp [Member]        
Principal amount   $ 1,280,000    
Seller [Member]        
Common stock value       $ 1,600,000,000
Earnout Participants [Member]        
Common stock value       $ 674,000,000
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 09, 2021
Sep. 20, 2021
Dec. 31, 2021
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2022
Mar. 08, 2023
Mar. 06, 2023
Related Party Transaction [Line Items]                      
Shares purchased during period 1,800,000 2,875,000                  
Shares purchased during period, value   $ 50,000                  
Proceeds from issuance of private placement $ 6,290,000           $ 6,290,000      
Officers compensation       $ 15,000   $ 8,667 30,000 $ 18,667      
Working capital loans             $ 1,500,000        
Sales units price per share $ 10.00     $ 10.00     $ 10.00        
Working capital loans outstanding             $ 0        
Unsecured Promissory Note [Member] | Jupiter Wellness Investment Corp [Member]                      
Related Party Transaction [Line Items]                      
Debt principle amount                   $ 200,000 $ 100,000
Chief Financial Officer [Member]                      
Related Party Transaction [Line Items]                      
Officers compensation         $ 5,000            
Management and Directors [Member] | Related Party [Member]                      
Related Party Transaction [Line Items]                      
Accrued expense related party       $ 13,667     $ 13,667   $ 8,667    
Private Placement [Member]                      
Related Party Transaction [Line Items]                      
Shares purchased during period 629,000                    
Proceeds from issuance of private placement $ 6,290,000                    
Common Class B [Member]                      
Related Party Transaction [Line Items]                      
Stock split description     the Company effected a 0.2 for 1 stock dividend for each share of Class B common stock outstanding (which has been accounted for as a stock split) of 575,000 shares of Class B common stock, which resulted in an aggregate of 3,450,000 shares of Class B common stock outstanding       0.2 for 1 stock dividend for each share of Class B common stock outstanding   0.2 for 1 stock dividend for each share of Class B common stock outstanding    
Shares issued as split stock     575,000                
Common stock, shares outstanding     3,450,000 3,450,000     3,450,000   3,450,000    
Shares issued as forfeited 450,000                    
Shares issued and outstanding percent 20.00%                    
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details Narrative)
Dec. 09, 2021
USD ($)
$ / shares
shares
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]  
Underwriting price per unit | $ / shares $ 0.20
Underwriting expense payment | $ $ 2,760,000
Marketing fees | $ $ 4,830,000
Over-Allotment Option [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]  
Shares purchase grant option | shares 1,800,000
Directors and Officers [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]  
Ccommon stock issuable, shares | shares 300,000
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
PROMISSORY NOTE (Details Narrative) - USD ($)
Mar. 08, 2023
Mar. 06, 2023
Dec. 05, 2022
Chijet Motor Company Inc [Member]      
Debt Instrument, Face Amount     $ 1,380,000
Chijet Motor Company Inc [Member] | Unsecured Promissory Note [Member]      
Debt Instrument, Face Amount   $ 1,180,000 $ 1,380,000
Jupiter Wellness Investment Corp [Member] | Unsecured Promissory Note [Member]      
Debt Instrument, Face Amount $ 200,000 $ 100,000  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
 1 Months Ended 6 Months Ended 12 Months Ended
Dec. 09, 2021
Dec. 31, 2021
Mar. 31, 2023
Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Shares authorized     111,000,000  
Share price per share $ 10.10   $ 0.0001  
Preferred stock, shares authorized     1,000,000 1,000,000
Preferred stock issued     0 0
Preferred stock outstanding     0 0
Common stock, terms of conversion     Each holder of a right will receive one-eighth (1/8) of one share of Class A common stock upon consummation of a Business Combination. In the event the Company will not be the surviving entity upon completion of the Company’s initial Business Combination, each holder of a public right will automatically receive the 1/8 share of Class A common stock underlying such public right (without paying any additional consideration); and each holder of a Private Placement Right or right underlying Units to be issued upon conversion of the Working Capital Loans will be required to affirmatively convert its rights in order to receive the 1/8 share of Class A common stock underlying each right (without paying any additional consideration)  
Warrants price per share $ 12.00      
Representative warrants 414,000      
Measurement Input, Price Volatility [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Warrant measurement inputs 35      
Measurement Input, Risk Free Interest Rate [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Warrant measurement inputs 1.18      
Measurement Input, Expected Term [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Warrant measurement inputs 5 years      
Representative Warrants [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Warrants price per share $ 2.626      
Fair value of representative warrants $ 1,087,164      
IPO [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Warrants price per share $ 12.00      
Warrants to purchase shares 276,000      
Representative warrants 414,000      
Common Class A [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Common stock, shares authorized     100,000,000 100,000,000
Common stock, shares issued     905,000 905,000
Common stock subject to redemption     13,800,000 13,800,000
Common stock, shares outstanding     905,000 905,000
Common Class B [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Common stock, shares authorized     10,000,000 10,000,000
Common stock, shares issued     3,450,000 3,450,000
Stock split description   the Company effected a 0.2 for 1 stock dividend for each share of Class B common stock outstanding (which has been accounted for as a stock split) of 575,000 shares of Class B common stock, which resulted in an aggregate of 3,450,000 shares of Class B common stock outstanding 0.2 for 1 stock dividend for each share of Class B common stock outstanding 0.2 for 1 stock dividend for each share of Class B common stock outstanding
Common stock, shares outstanding   3,450,000 3,450,000 3,450,000
Common stock, shares outstanding 450,000      
Shares issued and outstanding percent 20.00%      
Common Stock [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Common stock, shares authorized     110,000,000  
Preferred Stock [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Preferred stock, shares authorized     1,000,000  
XML 36 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001883799 2022-10-01 2023-03-31 0001883799 JWAC:ClassCommonStockParValue0.0001PerShareMember 2022-10-01 2023-03-31 0001883799 JWAC:RightsExchangeableForOneeighthOfOneShareOfClassCommonStockMember 2022-10-01 2023-03-31 0001883799 us-gaap:CommonClassAMember 2023-05-19 0001883799 us-gaap:CommonClassBMember 2023-05-19 0001883799 2023-03-31 0001883799 2022-09-30 0001883799 us-gaap:RelatedPartyMember 2023-03-31 0001883799 us-gaap:RelatedPartyMember 2022-09-30 0001883799 us-gaap:CommonClassAMember 2023-03-31 0001883799 us-gaap:CommonClassAMember 2022-09-30 0001883799 us-gaap:CommonClassBMember 2023-03-31 0001883799 us-gaap:CommonClassBMember 2022-09-30 0001883799 2021-10-01 2022-03-31 0001883799 2023-01-01 2023-03-31 0001883799 2022-01-01 2022-03-31 0001883799 us-gaap:CommonClassAMember 2022-10-01 2023-03-31 0001883799 us-gaap:CommonClassAMember 2021-10-01 2022-03-31 0001883799 us-gaap:CommonClassAMember 2023-01-01 2023-03-31 0001883799 us-gaap:CommonClassAMember 2022-01-01 2022-03-31 0001883799 us-gaap:CommonClassBMember 2022-10-01 2023-03-31 0001883799 us-gaap:CommonClassBMember 2021-10-01 2022-03-31 0001883799 us-gaap:CommonClassBMember 2023-01-01 2023-03-31 0001883799 us-gaap:CommonClassBMember 2022-01-01 2022-03-31 0001883799 us-gaap:PreferredStockMember 2021-09-30 0001883799 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-09-30 0001883799 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-09-30 0001883799 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001883799 us-gaap:RetainedEarningsMember 2021-09-30 0001883799 2021-09-30 0001883799 us-gaap:PreferredStockMember 2021-12-31 0001883799 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001883799 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001883799 us-gaap:RetainedEarningsMember 2021-12-31 0001883799 2021-12-31 0001883799 us-gaap:PreferredStockMember 2022-09-30 0001883799 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-09-30 0001883799 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-09-30 0001883799 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001883799 us-gaap:RetainedEarningsMember 2022-09-30 0001883799 us-gaap:PreferredStockMember 2022-12-31 0001883799 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001883799 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001883799 us-gaap:RetainedEarningsMember 2022-12-31 0001883799 2022-12-31 0001883799 us-gaap:PreferredStockMember 2021-10-01 2021-12-31 0001883799 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001883799 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001883799 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001883799 2021-10-01 2021-12-31 0001883799 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001883799 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001883799 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001883799 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001883799 us-gaap:PreferredStockMember 2022-10-01 2022-12-31 0001883799 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001883799 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001883799 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001883799 2022-10-01 2022-12-31 0001883799 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001883799 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001883799 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001883799 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001883799 us-gaap:PreferredStockMember 2022-03-31 0001883799 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-31 0001883799 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-03-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001883799 us-gaap:RetainedEarningsMember 2022-03-31 0001883799 2022-03-31 0001883799 us-gaap:PreferredStockMember 2023-03-31 0001883799 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-03-31 0001883799 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-03-31 0001883799 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001883799 us-gaap:RetainedEarningsMember 2023-03-31 0001883799 us-gaap:IPOMember 2021-12-08 2021-12-09 0001883799 2021-12-09 0001883799 us-gaap:OverAllotmentOptionMember 2021-12-08 2021-12-09 0001883799 2021-12-08 2021-12-09 0001883799 JWAC:PostTransactionMember 2021-12-09 0001883799 JWAC:AmericanStockTransferAndTrustCompanyLLCMember 2021-12-09 0001883799 us-gaap:CommonClassAMember 2021-12-09 0001883799 us-gaap:IPOMember 2021-12-09 0001883799 2022-10-26 0001883799 JWAC:SellerMember 2022-10-26 0001883799 JWAC:EarnoutParticipantsMember 2022-10-26 0001883799 JWAC:ChijetMotorCompanyIncMember 2022-12-05 0001883799 2022-12-05 0001883799 JWAC:JupiterWellnessAcquisitionCorpMember 2023-03-06 0001883799 2023-03-06 0001883799 srt:ScenarioForecastMember 2023-03-09 2023-06-08 0001883799 srt:ScenarioForecastMember 2023-06-08 0001883799 2021-09-19 2021-09-20 0001883799 us-gaap:CommonClassBMember 2021-12-01 2021-12-31 0001883799 us-gaap:CommonClassBMember 2021-12-31 0001883799 us-gaap:CommonClassBMember 2021-12-08 2021-12-09 0001883799 us-gaap:CommonClassBMember 2021-12-09 0001883799 us-gaap:PrivatePlacementMember 2021-12-08 2021-12-09 0001883799 srt:ChiefFinancialOfficerMember 2022-10-01 2022-12-31 0001883799 JWAC:ManagmentAndDirectorsMember us-gaap:RelatedPartyMember 2023-03-31 0001883799 JWAC:ManagmentAndDirectorsMember us-gaap:RelatedPartyMember 2022-09-30 0001883799 JWAC:UnsecuredPromissoryNoteMember JWAC:JupiterWellnessInvestmentCorpMember 2023-03-06 0001883799 JWAC:UnsecuredPromissoryNoteMember JWAC:JupiterWellnessInvestmentCorpMember 2023-03-08 0001883799 JWAC:DirectorsAndOfficersMember 2021-12-08 2021-12-09 0001883799 JWAC:UnsecuredPromissoryNoteMember JWAC:ChijetMotorCompanyIncMember 2022-12-05 0001883799 JWAC:UnsecuredPromissoryNoteMember JWAC:ChijetMotorCompanyIncMember 2023-03-06 0001883799 us-gaap:CommonStockMember 2023-03-31 0001883799 us-gaap:CommonClassBMember 2021-10-01 2022-09-30 0001883799 JWAC:RepresentativeWarrantsMember 2021-12-08 2021-12-09 0001883799 JWAC:RepresentativeWarrantsMember 2021-12-09 0001883799 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-09 0001883799 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-09 0001883799 us-gaap:MeasurementInputExpectedTermMember 2021-12-09 iso4217:USD shares iso4217:USD shares pure 0001883799 false --09-30 2023 Q2 10-Q true 2023-03-31 2023 false 001-41126 JUPITER WELLNESS ACQUISITION CORP. DE 87-2646504 1061 E. Indiantown Road Suite 110 Jupiter FL 33477 561 244-7100 Class A common stock, par value $0.0001 per share JWAC NASDAQ Rights, exchangeable for one-eighth of one share of Class A common stock JWACR NASDAQ Yes Yes Non-accelerated Filer true true false true 14705000 3450000 17731 610382 112529 251085 145433953 140173416 145564213 141034883 145564213 141034883 13667 8667 145000 40000 50000 546123 4830000 4830000 300000 2560000 8444790 4878667 8444790 4878667 144837830 139973416 0.0001 0.0001 1000000 1000000 0 0 0 0 0.0001 0.0001 100000000 100000000 905000 905000 905000 905000 91 91 0.0001 0.0001 10000000 10000000 3450000 3450000 3450000 3450000 345 345 345 345 -7718843 -3817636 -7718407 -3817200 145564213 141034883 30000 18667 15000 8667 100000 50000 1261207 346489 1155037 230366 1391207 365156 1220037 239033 2700587 -12845 1518128 -13391 1309380 -378001 298091 -252424 546123 308307 763257 -378001 -10216 -252424 14705000 9049231 14705000 14705000 3450000 3238324 3450000 3450000 3450000 3238324 3450000 3450000 0.04 -0.03 -0.00 -0.01 0.04 -0.03 -0.00 -0.01 0.04 -0.03 -0.00 -0.01 3450000 345 49655 -21015 28985 13800000 13800000 1380 137998620 138000000 3155917 3155917 276000 28 -28 -4830000 -4830000 629000 629000 63 6289937 6290000 -13800000 -1380 -139378620 -139380000 3026353 -3026353 -125577 -125577 905000 91 3450000 345 -3172945 -3172509 -252424 -252424 905000 91 3450000 345 -3425369 -3424933 905000 91 3450000 345 -3817636 -3817200 -1380000 -1380000 -1182459 -1182459 773473 773473 905000 91 3450000 345 -5606622 -5606186 905000 91 3450000 345 -5606622 -5606186 -1180000 -1180000 -922005 -922005 -10216 -10216 905000 91 3450000 345 -7718843 -7718407 905000 91 3450000 345 -7718843 -7718407 763257 -378001 2700587 13952 -26797 50000 546123 -138556 253119 5000 18667 105000 99687 -1092651 -499921 2360000 139380000 -2360000 -139380000 134844083 6290000 2560000 300000 -371650 2860000 140762433 -592651 882512 610382 363135 17731 1245647 2560000 139380000 4830000 2104464 <p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ztspejehMifb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 — <span id="xdx_82F_zF9wQE3Jumv3">ORGANIZATION AND BUSINESS OPERATIONS</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter Wellness Acquisition Corporation (the “Company”) is a blank check company incorporated on September 14, 2021, under the laws of the State of Delaware for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (a “Business Combination”). On October 26, 2022, the Company identified a target company for a Business Combination and activities in connection with the proposed acquisition of Chijet Inc., a Cayman Islands exempted company (see Note 4). The Company will not generate any operating revenues until after consummation of the initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the IPO.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023, the Company had not yet commenced any operations. All activity as of March 31, 2023, relates to the Company’s formation and the initial Public Offering (as defined below). The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected September 30 as its fiscal year end.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 9, 2021, the Company consummated its IPO of <span id="xdx_90D_eus-gaap--PartnersCapitalAccountUnitsAcquisitions_c20211208__20211209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zBhjwrW2Ikx3" title="IPO Units">13,800,000</span> units (the “Units” and, with respect to the shares of Class A common stock included in the Units, the “Public Shares”) at $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20211209_za20jCOUrGq" title="Sale of Stock, Price Per Share">10.00</span> per unit, which included <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211208__20211209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zrWKCSVQWS61" title="IPO Units">1,800,000</span> Units issued pursuant to the full exercise by the Underwriters (as defined below) of their over-allotment option, and the private sale of an aggregate of <span id="xdx_90C_eus-gaap--PartnersCapitalAccountUnitsSoldInPrivatePlacement_c20211208__20211209_zAhOObduehLl" title="Private placement units">629,000</span> Units (the “Private Placement Units” and with respect to the shares of Class A common stock included in the Units, the “Private Placement Shares”) to its sponsor, Jupiter Wellness Sponsor LLC (the “Sponsor”) and I-Bankers Securities, Inc. (“I-Bankers”) at a purchase price of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20211209_zU2aH9WPkCIa" title="Sale of Stock, Price Per Share">10.00</span> per Private Placement Unit, generating gross proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20211208__20211209_zAbdlORUGVG" title="Generating gross proceeds">6,290,000</span> to the Company that closed simultaneously with the closing of the IPO (see Note 3). The Company’s Units have been listed on the Nasdaq Global Market (“Nasdaq”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs amounted to $<span id="xdx_907_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_c20211208__20211209_zXhdkTNEEss8" title="Transaction costs">7,985,917</span> consisting of $<span id="xdx_90B_eus-gaap--PaymentsForUnderwritingExpense_c20211208__20211209_zVxcxVcxpBF" title="Underwriting discount and commission aggregate payable">2,760,000</span> in cash of underwriting commissions, $<span id="xdx_906_eus-gaap--MarketingExpense_c20211208__20211209_zG6Fhqh4gASa" title="Business combination marketing fee">4,830,000</span> of business combination marketing fee, and $<span id="xdx_907_eus-gaap--OtherCostAndExpenseOperating_c20211208__20211209_zRaScDQJ9G53" title="Other offering costs">395,917</span> of other offering costs. In addition, as of December 9, 2021, cash of $<span id="xdx_90F_eus-gaap--Capital_iI_c20211209_zyLqCQikakbi" title="Banking regulation, total capital, actual">1,630,676</span> was held outside of the Trust Account (as defined below) and is available for working capital purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete a Business Combination with one or more operating businesses or assets that together have an aggregate fair market value equal to at least <span id="xdx_906_eus-gaap--FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentCurrencies_iI_pid_dp_uPure_c20211209_zLnDu5ysXB4" title="Fair market value of net assets">80</span>% of the net assets held in the Trust Account (net of amounts disbursed to management for working capital purposes, if permitted, and excluding the amount of any deferred underwriting commissions) at the time of the Company’s signing a definitive agreement in connection with its initial Business Combination. The Company will only complete a Business Combination if the post-transaction company owns or acquires <span id="xdx_905_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20211209__us-gaap--BusinessAcquisitionAxis__custom--PostTransactionMember_zLxeVCcKzvcb" title="Post transaction ownership">50</span>% or more of the outstanding voting securities of the target or otherwise acquires an interest in the target business or assets sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the closing of the IPO on December 9, 2021, the Company deposited $<span id="xdx_903_eus-gaap--AssetsHeldInTrust_iI_c20211209__dei--LegalEntityAxis__custom--AmericanStockTransferAndTrustCompanyLLCMember_zimoA2j5plr1" title="Company net proceeds of IPO and private placement sale">139,380,000</span> ($<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20211209__dei--LegalEntityAxis__custom--AmericanStockTransferAndTrustCompanyLLCMember_zX9ysTo7PPqh" title="Price per unit sold">10.10</span> per Unit) from the proceeds of the IPO and certain proceeds of the sales of Private Placement Units in the trust account (“Trust Account”), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will provide its stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account (initially $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20211209_zWBpPdKYTzql" title="Price per unit sold">10.10</span> per share), calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The shares of Class A common stock will be recorded at redemption value and classified as temporary equity upon the completion of the IPO, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $<span id="xdx_908_ecustom--BusinessCombinationNetTangibleAssets_c20211208__20211209_z1iI59bK1F0g" title="Business combination net tangible assets">5,000,001</span> upon such completion of a Business Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to (i) waive its redemption rights with respect to their Private Placement Shares in connection with the completion of the Business Combination, (ii) waive its redemption rights with respect to their Private Placement Shares in connection with a stockholder vote to approve an amendment to the Company’s second amended and restated certificate of incorporation (a) to modify the substance or timing of the Company’s obligation to redeem <span id="xdx_90C_eus-gaap--FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareRedemptionRestrictionPercentage_iI_pid_dp_uPure_c20211209_zPQc45Elwpq6" title="Company obligation to redeem">100</span>% of the Public Shares if the Company does not complete the Business Combination within the Combination Period (as defined below) or (b) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination activity and (iii) waive its rights to liquidating distributions from the Trust Account with respect to their Private Placement Shares if the Company fails to complete the Business Combination within the Combination Period. In addition, the Sponsor has agreed to vote any share it held in favor of the Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, each public stockholder may elect to redeem its Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s second amended and restated certificate of incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares without the Company’s prior written consent.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will have until 12 months from the closing of the IPO (or 18 months from the closing of the IPO if the Company may extend the period of time to consummate a Business Combination) (the “Combination Period”) to complete a Business Combination. If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than 10 business days thereafter, redeem <span id="xdx_900_eus-gaap--FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareRedemptionRestrictionPercentage_iI_pid_dp_uPure_c20211209_zTmtkrLtS061" title="Company obligation to redeem">100</span>% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (less up to $<span id="xdx_906_eus-gaap--InterestIncomeMoneyMarketDeposits_c20211208__20211209_zwkki6dIAfgd" title="Interest to pay dissolution expenses">50,000</span> of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and requirements of other applicable law. On December 6, 2022, the Company extended the Combination Period until March 8, 2023. On March 6, 2023, the Company deposited another extension payment to extend the Combination Period until June 8, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sponsor has agreed to waive its liquidation rights with respect to the Founder Shares (as defined below) and Private Placement Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor acquires Public Shares in or after the IPO, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their business combination marketing fees (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the IPO price per Unit ($<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20211209_z4zeWzpTTPhi" title="Price per unit sold">10.10</span>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a third party for services rendered or products sold to the Company, or by a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20211209_zPi2NjDTHyU3" title="Price per unit sold">10.10</span> per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent auditors), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underwriting Agreement and Business Combination Marketing Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company engaged I-Bankers as the representative of the underwriters (the “Underwriters”) in the IPO of the Company’s Class A common stock, par value of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211209__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2x6f20KQ9Di" title="Common stock, par value">0.0001</span> per share (“Shares”), for $<span id="xdx_907_ecustom--ListingAmount_iI_pn6n6_c20211209_zooL5fpRekDf" title="IPO listing price">120</span> million and the simultaneous listing on Nasdaq. Pursuant to that certain underwriting agreement, I-Bankers acted as the representative of the Underwriters of the IPO for <span id="xdx_90C_ecustom--ListingUnits_iI_c20211209_z4KKnqeTaNu2" title="IPO listing units">12,000,000</span> Units at $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_c20211209_zFQn6f0iYaS" title="Private placement equivalent units price">10.00</span> per unit, plus an over-allotment option equal to <span id="xdx_90A_ecustom--OverAllotmentUnits_iI_dp_c20211209_zcMV41zs6KAd" title="Percentage of over-allotment units">15</span>% of the number of Units offered, or <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211208__20211209_zkYpSbVaxxX3" title="Stock issued during period, shares, new issues">1,800,000</span> Units, which was exercised in full simultaneously upon the closing of the IPO. The Company paid I-Bankers underwriters’ commission of $<span id="xdx_907_eus-gaap--InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions_c20211208__20211209_z06oy77CGqad" title="Underwriting commissions">2,760,000</span>, equal to <span id="xdx_90E_ecustom--GrossProceedsForServices_iI_dp_uPure_c20211209_z1a0xsLOAhj4" title="Percentage of gross proceeds raised for services">2.0</span>% of the gross proceeds raised in the IPO for such services upon the consummation of the IPO (exclusive of any applicable finders’ fees which might become payable).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the closing of the IPO, the Company issued to I-Bankers a five-year warrant to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211209_zxEfvDU0RzQi" title="Shares of Class A to purchase">414,000</span> Shares of Class A common stock, equal to <span id="xdx_905_ecustom--PercentageOWarrantsIssued_iI_dp_uPure_c20211209_zEdkh8YCmLzg" title="Representative Warrants percent">3.0</span>% of the Shares issued in the IPO (“Representative Warrants”). The exercise price of Representative Warrants is $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211209_zyx43HCKTjB3" title="Warrants price per share">12.00</span> per Share. In addition, I-Bankers was issued <span id="xdx_904_ecustom--RepresentativeShares2_iI_c20211209_ziDLP1OO2J34" title="Representative shares">276,000</span> shares of Class A common stock upon the consummation of IPO (“Representative Shares”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, under a business combination marketing agreement, the Company has engaged I-Bankers as an advisor in connection with the Business Combination and will pay I-Bankers a cash fee for such marketing services upon the consummation of the Business Combination in an amount equal to, in the aggregate, <span id="xdx_902_eus-gaap--RestrictedInvestmentsPercentOfNetAssets_iI_dp_uPure_c20211209_zVhgj6bPtGYi" title="Gross proceeds of the IPO">3.5</span>% of the gross proceeds of the IPO, including any proceeds from the exercise of the underwriters’ over-allotment option. The fee will become payable to the Underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern Consideration</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expects to incur significant costs in pursuit of its financing and acquisition plans. In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “<i>Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern</i>,” management has determined that if the Company is unsuccessful in consummating an initial business combination within the prescribed period of time from the closing of the IPO, the requirement that the Company cease all operations, redeem the public shares and thereafter liquidate and dissolve raises substantial doubt about the ability to continue as a going concern. The balance sheet does not include any adjustments that might result from the outcome of this uncertainty. Management has determined that the Company has funds that are sufficient to fund the working capital needs of the Company until the consummation of an initial business combination or the winding up of the Company as stipulated in the Company’s amended and restated memorandum of association. The accompanying financial statement has been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks and Uncertainties</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a target company, the specific impact is not readily determinable as of the date of this financial statement. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 13800000 10.00 1800000 629000 10.00 6290000 7985917 2760000 4830000 395917 1630676 0.80 0.50 139380000 10.10 10.10 5000001 1 1 50000 10.10 10.10 0.0001 120000000 12000000 10.00 0.15 1800000 2760000 0.020 414000 0.030 12.00 276000 0.035 <p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zxjW2Tlltuta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 — <span id="xdx_822_zIBZA6rlCxr9">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTo411yZP7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zMsUtJwReqJc">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of US Securities and Exchange Commission (“SEC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zWLJcpQzJ5bl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zns1gLS9akff">Emerging Growth Company Status</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act and modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--UseOfEstimates_z1jIXVLXtPq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zI5WRMYzaDy3">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zd22Nk95CYSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z0DQrRQPZAwj">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331_zC1RBbNbAEii" title="Cash">17,731</span> in cash as of March 31, 2023. The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84B_eus-gaap--MarketableSecuritiesPolicy_z75NuLxsBJ4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z7vMq78EFF57">Marketable Securities Held in Trust Account</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2023, substantially all of the assets held in the Trust Account were held in money market funds which are invested primarily in U.S. Treasury securities. All of the Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. At March 31, 2023, $<span id="xdx_906_eus-gaap--AssetsHeldInTrustCurrent_iI_c20230331_z9ynbP9WXkH5" title="Assets held in trust current">145,433,953</span> was held in the Trust Account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--OfferingCostsAssociatedWithTheIpoPolicyTextBlock_zusJ0pGDiRqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z9m1MWMK8xYk">Offering Costs Associated with the IPO</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the IPO that were directly related to the IPO. The Company incurred offering costs amounting to $<span id="xdx_909_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_c20211208__20211209_zseLUv3FNsb" title="Transaction costs">7,985,917</span> as a result of the IPO consisting of $<span id="xdx_90E_eus-gaap--InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions_c20211208__20211209_zfGcDuOHi1ja" title="Underwriting discount and commission aggregate payable">2,760,000</span> in cash of underwriting commissions, $<span id="xdx_90B_eus-gaap--MarketingExpense_c20211208__20211209_zNhihu5hl2V2" title="Business combination marketing fee">4,830,000</span> of business combination marketing fee, and $<span id="xdx_908_eus-gaap--OtherCostAndExpenseOperating_c20211208__20211209_zyPHsMGNyBg4" title="Other offering costs">395,917</span> of other offering costs. As of March 31, 2023, offering costs in the aggregate of $<span id="xdx_906_eus-gaap--PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts_c20221001__20230331_zujx9c0miwq6" title="Offering cost stockholders equity">3,155,917</span> have been charged to stockholders’ equity and $<span id="xdx_90E_eus-gaap--NoncashMergerRelatedCosts_c20221001__20230331_z8Kb0Hpm4YLa" title="Offering costs current liabilities">4,830,000</span> have been classified to current liabilities, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84D_ecustom--ClassACommonStockSubjectToPossibleRedemptionPolicyTextBlock_zP3eNtmRd1ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zJIJEG1olGsi">Class A Common Stock Subject to Possible Redemption</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the <span id="xdx_90A_eus-gaap--PartnersCapitalAccountUnitsAcquisitions_c20221001__20230331_zvMgWgAq0jgf" title="IPO shares">13,800,000</span> shares of Class A common stock sold as part of the Units in the IPO contain a redemption feature. In accordance with the Accounting Standards Codification 480-10-S99-3A “Classification and Measurement of Redeemable Securities”, redemption provisions not solely within the control of the Company require the security to be classified outside of permanent equity. Ordinary liquidation events, which involve the redemption and liquidation of all of the entity’s equity instruments, are excluded from the provisions of ASC 480. The change in the carrying value of redeemable shares of common stock resulted in charges against additional paid-in capital and accumulated deficit. Accordingly, at March 31, 2023, the shares of Class A common stock subject to possible redemption in the amount of $<span id="xdx_90C_eus-gaap--SharesSubjectToMandatoryRedemptionSettlementTermsAmount_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zxarn6byFfab" title="Common stock subject to possible redemption amount">144,837,830</span> were presented as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z0urp9g32Srb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zDEGMHZCGz6l">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the federal depository insurance coverage corporation limit of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20230331_zSxLuDYkxan" title="Federal depositoryh insurance amount">250,000</span>. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zh9fpQ6APBU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zATuEzUh0Mf9">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--BusinessCombinationsPolicy_z4qeKwpwCUx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z1x0A3e1K355">Business Combination Marketing Fee</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the business combination marketing agreement, the Company has engaged I-Bankers as an advisor in connection with the Business Combination and will pay I-Bankers a cash fee for such marketing services upon the consummation of the Business Combination in an amount equal to, in the aggregate, <span id="xdx_90F_eus-gaap--RestrictedInvestmentsPercentOfNetAssets_iI_pid_dp_uPure_c20211209_zWGrUkvjPOu" title="Gross proceeds of the IPO">3.5</span>% of the gross proceeds of the IPO, including any proceeds from the full or partial exercise of the underwriters’ over-allotment option.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zVUBVyL1Z8N8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zWaufWH2lOaf">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs to employees under FASB Accounting Standards Codification 718 “Compensation – Stock Compensation” (“ASC 718”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 14, 2021, the inception date, the Company adopted Accounting Standards Update (“ASU”) No. 2018-07 “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation – Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zi1m0L7kBeGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zcbAUdS2ERge">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the accounting and reporting requirements of FASB ASC, 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. There were no unrecognized tax benefits as of March 31, 2023 and September 30, 2022. Deferred tax assets were deemed to be de minimis as of March 31, 2023 and September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at March 31, 2023 and September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes was accrued for $<span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_c20221001__20230331_z2ogsiT6ievj" title="Income taxes">546,123</span> and $<span id="xdx_901_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20230331_zbXl0hoIyNOg" title="Income taxes">308,307</span> for the six and three months ended March 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_845_ecustom--WarrantsPolicyTextBlock_zbqZZjycOtP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z9NxmS71CWei">Warrants</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 480 requires a reporting entity to classify certain freestanding financial instruments as liabilities (or in some cases as assets). ASC 480-10-S99 addresses concerns raised by the SEC regarding the financial statement classification and measurement of securities subject to mandatory redemption requirements or whose redemption is outside the control of the issuer. If the stock subject to mandatory redemption provisions represents the only shares in the reporting entity, it must report instruments in the liabilities section of its statement of financial position. The stock subject must then describe them as shares subject to mandatory redemption, so as to distinguish the instruments from other financial statement liabilities. The Company concludes that the warrants to I-Bankers do not exhibit any of the above characteristics and, therefore, are outside the scope of ASC 480. The warrants were issued in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging — Contracts in Entity’s Own Equity. Such guidance provides that because the warrants meet the criteria for equity treatment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zvrL51RdZHQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zrwsLXY4fkTi">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statement.</span></p> <p id="xdx_85D_zv5bTlSu8Kr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTo411yZP7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zMsUtJwReqJc">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of US Securities and Exchange Commission (“SEC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zWLJcpQzJ5bl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zns1gLS9akff">Emerging Growth Company Status</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act and modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--UseOfEstimates_z1jIXVLXtPq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zI5WRMYzaDy3">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zd22Nk95CYSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z0DQrRQPZAwj">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331_zC1RBbNbAEii" title="Cash">17,731</span> in cash as of March 31, 2023. The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 17731 <p id="xdx_84B_eus-gaap--MarketableSecuritiesPolicy_z75NuLxsBJ4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z7vMq78EFF57">Marketable Securities Held in Trust Account</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2023, substantially all of the assets held in the Trust Account were held in money market funds which are invested primarily in U.S. Treasury securities. All of the Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. At March 31, 2023, $<span id="xdx_906_eus-gaap--AssetsHeldInTrustCurrent_iI_c20230331_z9ynbP9WXkH5" title="Assets held in trust current">145,433,953</span> was held in the Trust Account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 145433953 <p id="xdx_843_ecustom--OfferingCostsAssociatedWithTheIpoPolicyTextBlock_zusJ0pGDiRqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z9m1MWMK8xYk">Offering Costs Associated with the IPO</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the IPO that were directly related to the IPO. The Company incurred offering costs amounting to $<span id="xdx_909_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_c20211208__20211209_zseLUv3FNsb" title="Transaction costs">7,985,917</span> as a result of the IPO consisting of $<span id="xdx_90E_eus-gaap--InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions_c20211208__20211209_zfGcDuOHi1ja" title="Underwriting discount and commission aggregate payable">2,760,000</span> in cash of underwriting commissions, $<span id="xdx_90B_eus-gaap--MarketingExpense_c20211208__20211209_zNhihu5hl2V2" title="Business combination marketing fee">4,830,000</span> of business combination marketing fee, and $<span id="xdx_908_eus-gaap--OtherCostAndExpenseOperating_c20211208__20211209_zyPHsMGNyBg4" title="Other offering costs">395,917</span> of other offering costs. As of March 31, 2023, offering costs in the aggregate of $<span id="xdx_906_eus-gaap--PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts_c20221001__20230331_zujx9c0miwq6" title="Offering cost stockholders equity">3,155,917</span> have been charged to stockholders’ equity and $<span id="xdx_90E_eus-gaap--NoncashMergerRelatedCosts_c20221001__20230331_z8Kb0Hpm4YLa" title="Offering costs current liabilities">4,830,000</span> have been classified to current liabilities, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 7985917 2760000 4830000 395917 3155917 4830000 <p id="xdx_84D_ecustom--ClassACommonStockSubjectToPossibleRedemptionPolicyTextBlock_zP3eNtmRd1ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zJIJEG1olGsi">Class A Common Stock Subject to Possible Redemption</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the <span id="xdx_90A_eus-gaap--PartnersCapitalAccountUnitsAcquisitions_c20221001__20230331_zvMgWgAq0jgf" title="IPO shares">13,800,000</span> shares of Class A common stock sold as part of the Units in the IPO contain a redemption feature. In accordance with the Accounting Standards Codification 480-10-S99-3A “Classification and Measurement of Redeemable Securities”, redemption provisions not solely within the control of the Company require the security to be classified outside of permanent equity. Ordinary liquidation events, which involve the redemption and liquidation of all of the entity’s equity instruments, are excluded from the provisions of ASC 480. The change in the carrying value of redeemable shares of common stock resulted in charges against additional paid-in capital and accumulated deficit. Accordingly, at March 31, 2023, the shares of Class A common stock subject to possible redemption in the amount of $<span id="xdx_90C_eus-gaap--SharesSubjectToMandatoryRedemptionSettlementTermsAmount_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zxarn6byFfab" title="Common stock subject to possible redemption amount">144,837,830</span> were presented as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 13800000 144837830 <p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z0urp9g32Srb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zDEGMHZCGz6l">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the federal depository insurance coverage corporation limit of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20230331_zSxLuDYkxan" title="Federal depositoryh insurance amount">250,000</span>. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 250000 <p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zh9fpQ6APBU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zATuEzUh0Mf9">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--BusinessCombinationsPolicy_z4qeKwpwCUx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z1x0A3e1K355">Business Combination Marketing Fee</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the business combination marketing agreement, the Company has engaged I-Bankers as an advisor in connection with the Business Combination and will pay I-Bankers a cash fee for such marketing services upon the consummation of the Business Combination in an amount equal to, in the aggregate, <span id="xdx_90F_eus-gaap--RestrictedInvestmentsPercentOfNetAssets_iI_pid_dp_uPure_c20211209_zWGrUkvjPOu" title="Gross proceeds of the IPO">3.5</span>% of the gross proceeds of the IPO, including any proceeds from the full or partial exercise of the underwriters’ over-allotment option.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0.035 <p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zVUBVyL1Z8N8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zWaufWH2lOaf">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs to employees under FASB Accounting Standards Codification 718 “Compensation – Stock Compensation” (“ASC 718”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 14, 2021, the inception date, the Company adopted Accounting Standards Update (“ASU”) No. 2018-07 “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation – Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zi1m0L7kBeGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zcbAUdS2ERge">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the accounting and reporting requirements of FASB ASC, 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. There were no unrecognized tax benefits as of March 31, 2023 and September 30, 2022. Deferred tax assets were deemed to be de minimis as of March 31, 2023 and September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at March 31, 2023 and September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes was accrued for $<span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_c20221001__20230331_z2ogsiT6ievj" title="Income taxes">546,123</span> and $<span id="xdx_901_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20230331_zbXl0hoIyNOg" title="Income taxes">308,307</span> for the six and three months ended March 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 546123 308307 <p id="xdx_845_ecustom--WarrantsPolicyTextBlock_zbqZZjycOtP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z9NxmS71CWei">Warrants</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 480 requires a reporting entity to classify certain freestanding financial instruments as liabilities (or in some cases as assets). ASC 480-10-S99 addresses concerns raised by the SEC regarding the financial statement classification and measurement of securities subject to mandatory redemption requirements or whose redemption is outside the control of the issuer. If the stock subject to mandatory redemption provisions represents the only shares in the reporting entity, it must report instruments in the liabilities section of its statement of financial position. The stock subject must then describe them as shares subject to mandatory redemption, so as to distinguish the instruments from other financial statement liabilities. The Company concludes that the warrants to I-Bankers do not exhibit any of the above characteristics and, therefore, are outside the scope of ASC 480. The warrants were issued in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging — Contracts in Entity’s Own Equity. Such guidance provides that because the warrants meet the criteria for equity treatment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zvrL51RdZHQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zrwsLXY4fkTi">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statement.</span></p> <p id="xdx_807_ecustom--PublicOfferingTextBlock_zHGFnOMALk59" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 — <span id="xdx_823_znnDLaVMEync">Public Offering</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the IPO, the Company sold <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211208__20211209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zD02vQKhCijl" title="Sale of units at IPO">13,800,000</span> Units at a purchase price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20211209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zq6hfH5yTxxf" title="Sale of stock units">10.00</span> per Unit, which included <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211208__20211209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zykQ9sv6otp9" title="Sale of units at IPO">1,800,000</span> Units issued pursuant to the full exercise by the Underwriters of their over-allotment option, generating gross proceeds to the Company of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211208__20211209_zuOWzl70V2pg" title="Proceeds from issuance of public offering">138,000,000</span>. <span id="xdx_908_eus-gaap--SaleOfStockDescriptionOfTransaction_c20211208__20211209_zoaYMeQkgl88" title="Sale of stock, description">Each Unit consists of one share of Class A common stock of the Company, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211209__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zO4zUioViFS4" title="Common stock, par value">0.0001</span> per share (“Class A common stock”), and one right to receive one-eighth of one share of Class A common stock upon the consummation of the Company’s initial business combination (see Note 6)</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A total of $<span id="xdx_906_eus-gaap--CommonStockHeldInTrust_iI_c20211209__dei--LegalEntityAxis__custom--AmericanStockTransferAndTrustCompanyLLCMember_zbAbP5UIiPY4" title="Stock held in trust">139,380,000</span> of the net proceeds from the IPO and the sale of the Private Placement Units was placed in a U.S.-based Trust Account maintained by American Stock Transfer &amp; Trust Company, LLC, acting as trustee.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 13800000 10.00 1800000 138000000 Each Unit consists of one share of Class A common stock of the Company, par value $0.0001 per share (“Class A common stock”), and one right to receive one-eighth of one share of Class A common stock upon the consummation of the Company’s initial business combination (see Note 6) 0.0001 139380000 <p id="xdx_80A_eus-gaap--BusinessCombinationDisclosureTextBlock_zP1jdnm3J7Yc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 — <span id="xdx_824_zp5qyRz3b711">BUSINESS COMBINATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On October 26, 2022, Jupiter Wellness Acquisition Corp., a blank check, special purpose acquisition company incorporated as a Delaware corporation (the “Company”), issued a press release (the “Press Release”) announcing that the Company has entered into a definitive Business Combination Agreement (the “BCA”) on October 25, 2022, with Chijet Inc., a Cayman Islands exempted company (together with its subsidiaries, “Chijet”), each of the referenced holders of Chijet’s outstanding capital shares (collectively, the “Sellers”) and certain other parties formed in connection with the transactions contemplated by the BCA (the “Business Combination”), including Chijet Motor Company, Inc., a Cayman Islands exempted company and a wholly owned subsidiary of Chijet (“Pubco”). Chijet indirectly holds controlling interests in Shandong Baoya New Energy Vehicle Co., Ltd., a Chinese company (“Baoya”), which is a producer and manufacturer of electric vehicles and FAW Jilin Automobile Co., Ltd., a Chinese company (“FAW Jilin”), which manufactures and sells traditional fuel vehicles.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Subject to the terms and conditions of the BCA, Pubco will acquire all of the issued and outstanding shares of Chijet from the Sellers (“Purchased Shares”) in exchange for ordinary shares of Pubco and Chijet shall surrender for no consideration its shares in Pubco, such that Chijet becomes a wholly owned subsidiary of Pubco and the Sellers become shareholders of Pubco (the “Share Exchange”). Immediately thereafter, Merger Sub will merge with and into the Company, with the Company continuing as the surviving entity, as a result of which, (i) the Company shall become a wholly owned subsidiary of Pubco, and (ii) each issued and outstanding security of the Company immediately prior to the consummation of the Business Combination shall no longer be outstanding and shall automatically be cancelled, in exchange for the right of the holder thereof to receive a substantially equivalent security of Pubco (and with the holders of the Company’s publicly traded shares of Class A common stock, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221026_zlu2aAamIE5b" title="Common stock, par value">0.0001</span> per share (“Company Class A Common Stock”), that do not redeem their shares also receiving one (1) contingent value right (“CVR,” as defined in the BCA) for each share of Company Class A Common Stock held).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant to the BCA, at the closing, Pubco shall issue and deliver to the Sellers an aggregate number of Pubco ordinary shares (the “Exchange Shares”) with an aggregate value equal to One Billion Six Hundred Million U.S. Dollars ($<span id="xdx_90E_eus-gaap--CommonStockValue_iI_c20221026__srt--TitleOfIndividualAxis__custom--SellerMember_zFoG3AFZYm12" title="Common stock value">1,600,000,000</span>), with each Pubco ordinary share valued at the redemption price, and with each Seller receiving its pro rata share of the applicable Exchange Shares based on the number of Purchased Shares owned by such Seller, divided by the total number of purchased shares owned by all Sellers. However, the issuance to certain of the Sellers (the “Earnout Participants”) of Exchange Shares having a value of Six Hundred and Seventy Four Million U.S. Dollars ($<span id="xdx_902_eus-gaap--CommonStockValue_iI_c20221026__srt--TitleOfIndividualAxis__custom--EarnoutParticipantsMember_zALGFPKYIWCa" title="Common stock value">674,000,000</span>), with each of such shares being valued at the redemption price (such Pubco ordinary shares, subject to equitable adjustment for share splits, share dividends, combinations, recapitalizations and the like after the closing, including to account for any equity securities into which such shares are exchanged or converted, and together with the earnings thereof, the “Earnout Shares”), and each of the Earnout Participants shall have the contingent right to receive a pro rata portion of such Earnout Shares and earnings thereon (such pro rata allocation based on the number of Purchased Shares owned by such Earnout Participant, divided by the total number of Purchased shares owned by all Earnout Participants) based on Pubco and its subsidiaries achieving certain financial performance metrics over for calendar years 2023, 2024 and 2025 or meeting certain stock price metrics from the closing until 30 trading days after the date on which Pubco files its annual report for the calendar year ended December 31, 2023, 2024 and 2025, respectively with the SEC. To the extent that any such Earnout Shares are not earned, they (along with income thereon) will be redistributed pro rata to the holders of CVRs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On December 5, 2022, the company issued an unsecured promissory note (the “Note”) in the principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20221205__dei--LegalEntityAxis__custom--ChijetMotorCompanyIncMember_zfcCCzycz1J9" title="Principal amount">1,380,000</span> to Chijet (See Note 7 for further discussion.). In connection with the issuance of the Note, on December 5, 2022, the Company deposited an aggregate of $<span id="xdx_904_eus-gaap--AssetsHeldInTrust_iI_c20221205_zr7rYcVz8t93" title="Deposits into trust account">1,380,000</span> into the trust account of the Company for its public stockholders, which enables the Company to further extend the period of time it has to consummate its initial business combination by three months from December 8, 2022 to March 9, 2023 (the “Extension”). The Extension is the first of up to two three-month extensions permitted under the Company’s governing documents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 6, 2023, Jupiter Wellness Acquisition Corp. (the “Compan<b><i>y</i></b>”) issued two unsecured promissory note (the “Note”) in the principal amount totaling of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20230306__dei--LegalEntityAxis__custom--JupiterWellnessAcquisitionCorpMember_zGuXGqZeg3if" title="Principal amount">1,280,000</span> to Chijet, Inc. <span style="background-color: white">In connection with the issuance of the Note, on March 6, 2023, the Company deposited an aggregate of $<span id="xdx_90F_eus-gaap--Deposits_iI_c20230306_zLi1Om5WZLta" title="Deposits into trust account">1,380,000</span> into the trust account of the Company for its public stockholders, which enables the Company to further extend the period of time it has to consummate its initial business combination by three months from March 9, 2022 to June 8, 2023 (the “Extension”). The Extension is the second of up to two three-month extensions permitted under the Company’s governing documents. The $<span id="xdx_901_eus-gaap--ProceedsFromDecommissioningFund_c20230309__20230608__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zJDUxc6uieCd" title="Proceeds from trust account">100,000</span> balance of the $<span id="xdx_901_eus-gaap--Deposits_iI_c20230608__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zih4YbaouwB8" title="Deposits into trust account">1,380,000</span> was funded by the Company itself out of funds available in its operating account.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The business combination was not closed as of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023<span style="background-color: white">.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0.0001 1600000000 674000000 1380000 1380000 1280000 1380000 100000 1380000 <p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrGHh4T7Tn1e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 </b>— <b><span id="xdx_828_zrcqSbiTpaI2">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Founder Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 20, 2021, the Sponsor purchased <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210919__20210920_zNF9OgjROotl" title="Shares purchased during period">2,875,000</span> shares of the Company’s Class B common stock (the “Founder Shares”) for an aggregate purchase price of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210919__20210920_zLf1Ry0F27ej" title="Shares purchased during period, value">50,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, <span id="xdx_907_eus-gaap--StockholdersEquityNoteStockSplit_c20211201__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zwSd3vz0k1u2" title="Stock split description">the Company effected a 0.2 for 1 stock dividend for each share of Class B common stock outstanding (which has been accounted for as a stock split) of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockSplits_c20211201__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z00rXIdK8H8h" title="Shares issued as split stock">575,000</span> shares of Class B common stock, which resulted in an aggregate of <span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z0c6eh7PeJg3" title="Common stock, shares outstanding">3,450,000</span> shares of Class B common stock outstanding</span>. All share and associated amounts have been retroactively restated to reflect the share dividend.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Founder Shares include an aggregate of up to <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20211208__20211209__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zE5DBzL62kDb" title="Shares issued as forfeited">450,000</span> shares of Class B common stock subject to forfeiture by the Sponsor to the extent that the underwriters’ over-allotment is not exercised in full or in part, so that the number of Founder Shares will collectively represent <span id="xdx_90B_ecustom--SharesIssuedAndOutstandingPercent_iI_pid_dp_uPure_c20211209__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zCbCWiIpSS75" title="Shares issued and outstanding percent">20</span>% of the Company’s issued and outstanding shares upon the completion of the IPO. On December 9, 2021, the Underwriter exercised the over-allotment option in full. As a result, no Founder Shares is subject to for forfeiture (see Note 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Private Placement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently with the closing of the IPO, the Sponsor and the Underwriters purchased an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211208__20211209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z0xKWopEhix8" title="Shares purchased during period">629,000</span> Private Placement Units, generating gross proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20211208__20211209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zViXLXvredi" title="Proceeds from issuance of private placement">6,290,000</span> in aggregate in a private placement. Each Private Placement Unit will consist of one share of Class A common stock and one right. Each right underlying the Private Placement Unit (the “Private Placement Right”) will entitle the holder to receive one-eighth of one share of Class A common stock at the closing of a Business Combination. The proceeds from the sale of the Private Placement Units have been added to the net proceeds from the IPO held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Placements Units and all underlying securities will expire worthless.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Private Placement Units (including the underlying Private Placement Rights, the Private Placement Shares and the shares of Class A common stock issuable upon conversion of the Private Placement Rights) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination (except as described under the section of the IPO prospectus entitled “Principal Stockholders — Restrictions on Transfers of Founder Shares and Private Placement Units”). Following such period, the Private Placement Units (including the underlying Private Placement Rights, the Private Placement Shares and the shares of Class A common stock issuable upon conversion of the Private Placement Rights) will be transferable, assignable or salable, except that the Private Placement Units will not trade.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued Expenses - Related Parties</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the executed Offer Letters, the Company agreed to pay the Company’s Chief Financial Officer $<span id="xdx_909_eus-gaap--OfficersCompensation_c20221001__20221231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zzOCgaShYs02" title="Officers compensation">5,000</span> in cash per month starting from December 9, 2021. As of March 31, 2023 and September 30, 2022, the Company had accrued expenses – related parties in amount of $<span id="xdx_90F_eus-gaap--AccountsPayableCurrent_iI_c20230331__srt--TitleOfIndividualAxis__custom--ManagmentAndDirectorsMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_z4ygLRv0341b" title="Accrued expense related party">13,667</span> and $<span id="xdx_908_eus-gaap--AccountsPayableCurrent_iI_c20220930__srt--TitleOfIndividualAxis__custom--ManagmentAndDirectorsMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_zxBxKZJ6SZ7g" title="Accrued expense related party">8,667</span> in connection with the accrued compensation to the Company’s management and directors, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Working Capital Loans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or certain of the Company’s officers and directors or their affiliates may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $<span id="xdx_907_ecustom--WorkingCapitalLoans_pn5n6_c20221001__20230331_zxW4mhmGmqyl" title="Working capital loans">1.5</span> million of such Working Capital Loans may be convertible into private placement-equivalent units at a price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20230331_zAJCbGx9Wecf" title="Sales units price per share">10.00</span> per unit at the option of the lender. Such units would be identical to the Private Placement Units. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of March 31, 2023, <span id="xdx_90A_ecustom--WorkingCapitalLoansOutstanding_do_c20221001__20230331_zdKoDiEiAglj" title="Working capital loans outstanding">no</span> Working Capital Loans were outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Promissory Note - Related Party</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 6, 2023, the Company issued an unsecured promissory note in the principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20230306__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--JupiterWellnessInvestmentCorpMember_zkFxiRMCNsCe" title="Debt principle amount">100,000</span> to Jupiter Wellness Investment Corp., a wholly owned subsidiary of Jupiter Wellness, Inc. The Note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 8, 2023, the Company issued an unsecured promissory note in the principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20230308__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--JupiterWellnessInvestmentCorpMember_zS7PkUCoWll1" title="Debt principle amount">200,000</span> to Jupiter Wellness, Inc. This note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 2875000 50000 the Company effected a 0.2 for 1 stock dividend for each share of Class B common stock outstanding (which has been accounted for as a stock split) of 575,000 shares of Class B common stock, which resulted in an aggregate of 3,450,000 shares of Class B common stock outstanding 575000 3450000 450000 0.20 629000 6290000 5000 13667 8667 1500000 10.00 0 100000 200000 <p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zbcz6gzr3I97" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 — <span id="xdx_82F_z8VlgYcef3B7">COMMITMENTS AND CONTINGENCIES</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of the Founder Shares, Private Placement Units (and their underlying securities), the Representative Shares, the Representative Warrants (and their underlying securities), the <span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesToBeIssuedForServices_c20211208__20211209__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zonxJCISJ8Yi" title="Ccommon stock issuable, shares">300,000</span> shares of Class A common stock issuable to the Company’s directors and officers within 10 days following the Business Combination and any Units that may be issued upon conversion of the Working Capital Loans (and their underlying securities) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of the IPO requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to Class A common stock). The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underwriting Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had granted the Underwriters a 30-day option from the date of IPO to purchase up to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211208__20211209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zFfZ9nG7appd" title="Shares purchase grant option">1,800,000</span> additional Units to cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously upon the closing of the IPO, the Underwriters exercised the over-allotment option in full. As such, the Underwriters were paid an underwriting discount and commission of $<span id="xdx_90A_ecustom--UnderwritingPricePerUnit_iI_c20211209_zxfdxM4z19O5" title="Underwriting price per unit">0.20</span> per Unit, or $<span id="xdx_90C_eus-gaap--PaymentsForUnderwritingExpense_c20211208__20211209_zKHdQ1KxDH42" title="Underwriting expense payment">2,760,000</span> in the aggregate payable upon the closing of the IPO, and I-Bankers was entitled to a business combination marketing fee of $<span id="xdx_902_eus-gaap--MarketingExpense_c20211208__20211209_zqw7C8vr4qr9" title="Marketing fees">4,830,000</span> in the aggregate, which is held in the Trust Account and payable upon completion of the Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 300000 1800000 0.20 2760000 4830000 <p id="xdx_806_ecustom--PromissoryNoteTextBlock_zvYAKP05y0j8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 — <span id="xdx_820_zLBLZeglzC19">PROMISSORY NOTE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 5, 2022, the company issued an unsecured promissory note (the “Note”) in the principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20221205__dei--LegalEntityAxis__custom--ChijetMotorCompanyIncMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteMember_zpDT1XjTWNoj">1,380,000</span> to Chijet. Chijet, entered into a business combination agreement with the Company, among others, on October 25, 2022. The Note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 6, 2023, the company issued an unsecured promissory note in the principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20230306__dei--LegalEntityAxis__custom--ChijetMotorCompanyIncMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteMember_zyeapToj9Km4">1,180,000</span> to Chijet. The Note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 6, 2023, the Company issued an unsecured promissory note in the principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20230306__dei--LegalEntityAxis__custom--JupiterWellnessInvestmentCorpMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteMember_zbBwVByVrzN4">100,000</span> to Jupiter Wellness Investment Corp., a wholly owned subsidiary of Jupiter Wellness, Inc. The Note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 8, 2023, the Company issued an unsecured promissory note in the principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20230308__dei--LegalEntityAxis__custom--JupiterWellnessInvestmentCorpMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteMember_zRvNFjEuRX65">200,000</span> to Jupiter Wellness, Inc. This note is non-interest bearing and payable in cash upon the earlier of the closing of the Company’s initial business combination and date of liquidation of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1380000 1180000 100000 200000 <p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zmGGYfCRUHT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 — <span id="xdx_823_zeP9cUIXMs9a">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is authorized to issue a total of <span id="xdx_909_eus-gaap--CapitalUnitsAuthorized_iI_c20230331_zzp5XdkaE6li" title="Shares authorized">111,000,000</span> shares, par value of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20230331_zn1z3VeWqa8l" title="Share price per share">0.0001</span> per share, consisting of (a) <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXxc1ZocZBHi" title="Common stock, shares authorized">110,000,000</span> shares of common stock, including (i) <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zme2vQRj73dc" title="Common stock, shares authorized">100,000,000</span> shares of Class A common stock, and (ii) <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zsrsGHA1Vyjc" title="Common stock, shares authorized">10,000,000</span> shares of Class B common stock, and (b) <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zdAphDz8Ru3j" title="Preferred stock, shares authorized">1,000,000</span> shares of preferred stock (the “Preferred Stock”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023 and September 30, 2022, there were <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z55SQL231aze" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zFjkthRUiu2e" title="Common stock, shares issued">905,000</span></span> shares of Class A common stock and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zC0YHXsJKck" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zm6MNMlOqOp6" title="Common stock, shares issued">3,450,000</span></span> shares of Class B common stock issued and outstanding, which such amount having been restated to reflect a <span id="xdx_904_eus-gaap--StockholdersEquityNoteStockSplit_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zvWFvyGhYJv9" title="Stock split description"><span id="xdx_900_eus-gaap--StockholdersEquityNoteStockSplit_c20221001__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_znpVBBi13W2l" title="Stock split description">0.2 for 1 stock dividend for each share of Class B common stock outstanding</span></span> in December 2021 (excluding <span id="xdx_907_eus-gaap--TreasuryStockCommonShares_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zUHFKs2fneAi" title="Common stock subject to redemption"><span id="xdx_901_eus-gaap--TreasuryStockCommonShares_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zX1ix0z6Vbdh" title="Common stock subject to redemption">13,800,000</span></span> shares of Class A common stock subject to possible redemption).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of the <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zzU4FoZJdQSh" title="Common stock, shares outstanding">3,450,000</span> shares of Class B common stock outstanding, an aggregate of up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20211208__20211209__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zmV3yyvkr68e" title="Common stock, shares outstanding">450,000</span> shares of Class B common stock were subject to forfeiture, to the extent that the underwriters’ over-allotment option is not exercised in full or in part, so that the Sponsor would collectively own <span id="xdx_909_ecustom--SharesIssuedAndOutstandingPercent_iI_pid_dp_c20211209__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zPGg1yAnALMl" title="Shares issued and outstanding percent">20</span>% of the Company’s issued and outstanding common stock after the IPO (assuming Sponsor does not purchase any Public Shares in the IPO). As a result of the Underwriters’ full exercise of the over-allotment option on December 9, 2021, no share of Class B common stock is subject to forfeiture.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023 and September 30, 2022, <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20230331_z0IWwywW2oCk" title="Preferred stock issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230331_zoQUCmGH6dO5" title="Preferred stock outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20220930_z1vKzMtATMJ1" title="Preferred stock issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220930_zTwzFCYwhsoh" title="Preferred stock outstanding">no</span></span></span></span> share of Preferred Stock was issued or outstanding. The designations, voting and other rights and preferences of the Preferred Stock may be determined from time to time by the Company’s board of directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--CommonStockConversionFeatures_c20221001__20230331_zobC8f41Iri9" title="Common stock, terms of conversion">Each holder of a right will receive one-eighth (1/8) of one share of Class A common stock upon consummation of a Business Combination. In the event the Company will not be the surviving entity upon completion of the Company’s initial Business Combination, each holder of a public right will automatically receive the 1/8 share of Class A common stock underlying such public right (without paying any additional consideration); and each holder of a Private Placement Right or right underlying Units to be issued upon conversion of the Working Capital Loans will be required to affirmatively convert its rights in order to receive the 1/8 share of Class A common stock underlying each right (without paying any additional consideration)</span>. If the Company is unable to complete an initial Business Combination within the required time period and public stockholders redeem the public shares for the funds held in the Trust Account, holders of rights will not receive any such funds in exchange for their rights and the rights will expire worthless. The Company will not issue fractional shares upon conversion of the rights. If, upon conversion of the rights, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exchange, comply with Section 155 of the Delaware General Corporation Law. The Company will make the determination of how to treat fractional shares at the time of its initial Business Combination and will include such determination in the proxy materials that it will send to stockholders for their consideration of such initial Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure to deliver securities to the holders of the rights upon consummation of a Business Combination. Additionally, in no event will the Company be required to net cash settle the rights. Accordingly, the rights may expire worthless.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Representative Warrants and Representative Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the closing of the IPO, the Company issued to the Underwriters Representative Warrants, the exercise price of which will be $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ziwxMdnzZlfa" title="Warrants price per share">12.00</span> per Share, and <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zA5TxHb5EZ23" title="Warrants to purchase shares">276,000</span> Representative Shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Representative Warrants shall be exercisable, in whole or in part, commencing the later of December 9, 2022 and the closing of the Company’s initial Business Combination and terminating on December 9, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounted for the <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMwBOFEYrRpf" title="Representative warrants">414,000</span> warrants as an expense of the IPO resulting in a charge directly to stockholders’ equity. The fair value of Representative Warrants was estimated to be approximately $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20211208__20211209__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsMember_zuaSflZY6e0j" title="Fair value of representative warrants">1,087,164</span> (or $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211209__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsMember_zUH0xibIEmf3" title="Warrants price per share">2.626</span> per warrant) using the Black-Scholes option-pricing model. The fair value of the Representative Warrants granted to the Underwriters was estimated as of the date of grant using the following assumptions: (1) expected volatility of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211209__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z7s6G6ot16P4" title="Warrant measurement inputs">35</span>%, (2) risk-free interest rate of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211209__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zo3UIBaYbvSe" title="Warrant measurement inputs">1.18</span>% and (3) expected life of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20211209__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2APajaSfdy3" title="Warrant measurement inputs">five years</span>. The Representative Warrants and the shares of Class A common stock underlying Representative Warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up immediately following December 9, 2021 pursuant to FINRA Rule 511€)(1). The Representative</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants grants to holders demand and “piggy back” rights for periods of five and seven years from December 9, 2021. The Company will bear all fees and expenses attendant to registering the securities, other than underwriting commissions which will be paid for by the holders themselves. The exercise price and number of shares issuable upon exercise of the Representative Warrants may be adjusted in certain circumstances including in the event of a stock dividend, or the Company’s recapitalization, reorganization, merger or consolidation. However, the Representative Warrants will not be adjusted for issuances of Class A common stock at a price below its exercise price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Underwriters agreed not to transfer, assign or sell any of the Representative Shares without the Company’s prior written consent until the completion of the Business Combination. The Underwriters agreed (i) to waive its redemption rights with respect to such shares in connection with the completion of the initial Business Combination and (ii) to waive its rights to liquidating distributions from the Trust Account with respect to the Representative Shares if the Company fails to complete its initial Business Combination within Combination Period. The shares have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following December 9, 2021 pursuant to FINRA Rule 5110(e)(1).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 111000000 0.0001 110000000 100000000 10000000 1000000 905000 905000 3450000 3450000 0.2 for 1 stock dividend for each share of Class B common stock outstanding 0.2 for 1 stock dividend for each share of Class B common stock outstanding 13800000 13800000 3450000 450000 0.20 0 0 0 0 Each holder of a right will receive one-eighth (1/8) of one share of Class A common stock upon consummation of a Business Combination. In the event the Company will not be the surviving entity upon completion of the Company’s initial Business Combination, each holder of a public right will automatically receive the 1/8 share of Class A common stock underlying such public right (without paying any additional consideration); and each holder of a Private Placement Right or right underlying Units to be issued upon conversion of the Working Capital Loans will be required to affirmatively convert its rights in order to receive the 1/8 share of Class A common stock underlying each right (without paying any additional consideration) 12.00 276000 414000 1087164 2.626 35 1.18 P5Y <p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zkHS3uch6xQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 — <span id="xdx_822_zgtNgEiLPPj9">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statement was available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statement.</span></p> EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 38 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 118 183 1 false 28 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://jupiterwellness.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://jupiterwellness.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://jupiterwellness.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://jupiterwellness.com/role/StatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Statements of Changes in Stockholders' (Deficit) Sheet http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit Statements of Changes in Stockholders' (Deficit) Statements 5 false false R6.htm 00000006 - Statement - Statements of Changes in Stockholders' (Deficit) (Parenthetical) Sheet http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficitParenthetical Statements of Changes in Stockholders' (Deficit) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Statements of Cash Flows Sheet http://jupiterwellness.com/role/StatementsOfCashFlows Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - ORGANIZATION AND BUSINESS OPERATIONS Sheet http://jupiterwellness.com/role/OrganizationAndBusinessOperations ORGANIZATION AND BUSINESS OPERATIONS Notes 8 false false R9.htm 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://jupiterwellness.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - Public Offering Sheet http://jupiterwellness.com/role/PublicOffering Public Offering Notes 10 false false R11.htm 00000011 - Disclosure - BUSINESS COMBINATION Sheet http://jupiterwellness.com/role/BusinessCombination BUSINESS COMBINATION Notes 11 false false R12.htm 00000012 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://jupiterwellness.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 12 false false R13.htm 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://jupiterwellness.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 00000014 - Disclosure - PROMISSORY NOTE Sheet http://jupiterwellness.com/role/PromissoryNote PROMISSORY NOTE Notes 14 false false R15.htm 00000015 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://jupiterwellness.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 15 false false R16.htm 00000016 - Disclosure - SUBSEQUENT EVENTS Sheet http://jupiterwellness.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 16 false false R17.htm 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - ORGANIZATION AND BUSINESS OPERATIONS (Details Narrative) Sheet http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative ORGANIZATION AND BUSINESS OPERATIONS (Details Narrative) Details http://jupiterwellness.com/role/OrganizationAndBusinessOperations 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies 19 false false R20.htm 00000020 - Disclosure - Public Offering (Details Narrative) Sheet http://jupiterwellness.com/role/PublicOfferingDetailsNarrative Public Offering (Details Narrative) Details http://jupiterwellness.com/role/PublicOffering 20 false false R21.htm 00000021 - Disclosure - BUSINESS COMBINATION (Details Narrative) Sheet http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative BUSINESS COMBINATION (Details Narrative) Details http://jupiterwellness.com/role/BusinessCombination 21 false false R22.htm 00000022 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://jupiterwellness.com/role/RelatedPartyTransactions 22 false false R23.htm 00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://jupiterwellness.com/role/CommitmentsAndContingencies 23 false false R24.htm 00000024 - Disclosure - PROMISSORY NOTE (Details Narrative) Sheet http://jupiterwellness.com/role/PromissoryNoteDetailsNarrative PROMISSORY NOTE (Details Narrative) Details http://jupiterwellness.com/role/PromissoryNote 24 false false R25.htm 00000025 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://jupiterwellness.com/role/StockholdersEquity 25 false false All Reports Book All Reports form10-q.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm jwac-20230331.xsd jwac-20230331_cal.xml jwac-20230331_def.xml jwac-20230331_lab.xml jwac-20230331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 42 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 415, "http://xbrl.sec.gov/dei/2023": 36 }, "contextCount": 118, "dts": { "calculationLink": { "local": [ "jwac-20230331_cal.xml" ] }, "definitionLink": { "local": [ "jwac-20230331_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "jwac-20230331_lab.xml" ] }, "presentationLink": { "local": [ "jwac-20230331_pre.xml" ] }, "schema": { "local": [ "jwac-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 299, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 81, "http://jupiterwellness.com/20230331": 27, "http://xbrl.sec.gov/dei/2023": 5, "total": 113 }, "keyCustom": 33, "keyStandard": 150, "memberCustom": 13, "memberStandard": 15, "nsprefix": "JWAC", "nsuri": "http://jupiterwellness.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://jupiterwellness.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "JWAC:PublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Public Offering", "menuCat": "Notes", "order": "10", "role": "http://jupiterwellness.com/role/PublicOffering", "shortName": "Public Offering", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "JWAC:PublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - BUSINESS COMBINATION", "menuCat": "Notes", "order": "11", "role": "http://jupiterwellness.com/role/BusinessCombination", "shortName": "BUSINESS COMBINATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "12", "role": "http://jupiterwellness.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "13", "role": "http://jupiterwellness.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "JWAC:PromissoryNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - PROMISSORY NOTE", "menuCat": "Notes", "order": "14", "role": "http://jupiterwellness.com/role/PromissoryNote", "shortName": "PROMISSORY NOTE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "JWAC:PromissoryNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "menuCat": "Notes", "order": "15", "role": "http://jupiterwellness.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "16", "role": "http://jupiterwellness.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "17", "role": "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "span", "p", "JWAC:ClassACommonStockSubjectToPossibleRedemptionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PartnersCapitalAccountUnitsAcquisitions", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - ORGANIZATION AND BUSINESS OPERATIONS (Details Narrative)", "menuCat": "Details", "order": "18", "role": "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "shortName": "ORGANIZATION AND BUSINESS OPERATIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-09", "decimals": "0", "lang": null, "name": "us-gaap:Capital", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "19", "role": "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "JWAC:OfferingCostsAssociatedWithTheIpoPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:NoncashMergerRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://jupiterwellness.com/role/BalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-10-012021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Public Offering (Details Narrative)", "menuCat": "Details", "order": "20", "role": "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative", "shortName": "Public Offering (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "JWAC:PublicOfferingTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-12-082021-12-09", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-10-26", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - BUSINESS COMBINATION (Details Narrative)", "menuCat": "Details", "order": "21", "role": "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative", "shortName": "BUSINESS COMBINATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-06", "decimals": "0", "lang": null, "name": "us-gaap:Deposits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-12-082021-12-09", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "22", "role": "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-09-192021-09-20", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-09", "decimals": "INF", "first": true, "lang": null, "name": "JWAC:UnderwritingPricePerUnit", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-09", "decimals": "INF", "first": true, "lang": null, "name": "JWAC:UnderwritingPricePerUnit", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-05_custom_ChijetMotorCompanyIncMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - PROMISSORY NOTE (Details Narrative)", "menuCat": "Details", "order": "24", "role": "http://jupiterwellness.com/role/PromissoryNoteDetailsNarrative", "shortName": "PROMISSORY NOTE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "JWAC:PromissoryNoteTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-06_custom_ChijetMotorCompanyIncMember_custom_UnsecuredPromissoryNoteMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CapitalUnitsAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "menuCat": "Details", "order": "25", "role": "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CapitalUnitsAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OfficersCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://jupiterwellness.com/role/StatementsOfOperations", "shortName": "Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-03-31", "decimals": "0", "lang": null, "name": "JWAC:FranchiseTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember_us-gaap_CommonClassBMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Statements of Changes in Stockholders' (Deficit)", "menuCat": "Statements", "order": "5", "role": "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "shortName": "Statements of Changes in Stockholders' (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-10-012021-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember", "decimals": "0", "lang": null, "name": "us-gaap:PartnersCapitalAccountPublicSaleOfUnits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-10-012021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Statements of Changes in Stockholders' (Deficit) (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficitParenthetical", "shortName": "Statements of Changes in Stockholders' (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://jupiterwellness.com/role/StatementsOfCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:MarketableSecuritiesGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - ORGANIZATION AND BUSINESS OPERATIONS", "menuCat": "Notes", "order": "8", "role": "http://jupiterwellness.com/role/OrganizationAndBusinessOperations", "shortName": "ORGANIZATION AND BUSINESS OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "9", "role": "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 28, "tag": { "JWAC_AccruedExpenseRelatedParty": { "auth_ref": [], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expense related party.", "label": "Accrued expense-related party" } } }, "localname": "AccruedExpenseRelatedParty", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "JWAC_AdditionalAmountDepositedIntoTrust": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional amount deposited into trust.", "label": "Additional amount deposited into trust" } } }, "localname": "AdditionalAmountDepositedIntoTrust", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "JWAC_AmericanStockTransferAndTrustCompanyLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Stock Transfer & Trust Company, LLC [Member]", "label": "American Stock Transfer & Trust Company, LLC [Member]" } } }, "localname": "AmericanStockTransferAndTrustCompanyLLCMember", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative" ], "xbrltype": "domainItemType" }, "JWAC_BusinessCombinationNetTangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination net tangible assets.", "label": "Business combination net tangible assets" } } }, "localname": "BusinessCombinationNetTangibleAssets", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "JWAC_ChijetMotorCompanyIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chijet Motor Company Inc [Member]", "label": "Chijet Motor Company Inc [Member]" } } }, "localname": "ChijetMotorCompanyIncMember", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative", "http://jupiterwellness.com/role/PromissoryNoteDetailsNarrative" ], "xbrltype": "domainItemType" }, "JWAC_ClassACommonStockSubjectToPossibleRedemptionPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class A Common Stock Subject To Possible Redemption [PolicyTextBlock]", "label": "Class A Common Stock Subject to Possible Redemption" } } }, "localname": "ClassACommonStockSubjectToPossibleRedemptionPolicyTextBlock", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "JWAC_ClassCommonStockParValue0.0001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class A common stock, par value $0.0001 per share.", "label": "Class A common stock, par value $0.0001 per share" } } }, "localname": "ClassCommonStockParValue0.0001PerShareMember", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "domainItemType" }, "JWAC_DeferredUnderwritingFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriting fee.", "label": "Deferred Underwriting Fee" } } }, "localname": "DeferredUnderwritingFee", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "JWAC_DeferredUnderwritingFeeCurrent": { "auth_ref": [], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriting fee current.", "label": "Deferred underwriting fee" } } }, "localname": "DeferredUnderwritingFeeCurrent", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "JWAC_DirectorsAndOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Directors and Officers [Member]", "label": "Directors and Officers [Member]" } } }, "localname": "DirectorsAndOfficersMember", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "JWAC_DisclosurePromissoryNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note" } } }, "localname": "DisclosurePromissoryNoteAbstract", "nsuri": "http://jupiterwellness.com/20230331", "xbrltype": "stringItemType" }, "JWAC_DisclosurePublicOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Public Offering" } } }, "localname": "DisclosurePublicOfferingAbstract", "nsuri": "http://jupiterwellness.com/20230331", "xbrltype": "stringItemType" }, "JWAC_EarnoutParticipantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnout Participants [Member]", "label": "Earnout Participants [Member]" } } }, "localname": "EarnoutParticipantsMember", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "domainItemType" }, "JWAC_EmergingGrowthCompanyStatusPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging Growth Company Status [PolicyTextBlock]", "label": "Emerging Growth Company Status" } } }, "localname": "EmergingGrowthCompanyStatusPolicyTextBlock", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "JWAC_FranchiseTax": { "auth_ref": [], "calculation": { "http://jupiterwellness.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Franchise tax.", "label": "Franchise Tax" } } }, "localname": "FranchiseTax", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "JWAC_FranchiseTaxPayable": { "auth_ref": [], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Franchise tax payable.", "label": "Franchise tax Payable" } } }, "localname": "FranchiseTaxPayable", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "JWAC_FundsAttributableToCommonStockSubjectToRedemption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Funds attributable to common stock subject to redemption.", "label": "Funds attributable to common stock subject to redemption" } } }, "localname": "FundsAttributableToCommonStockSubjectToRedemption", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "JWAC_GrossProceedsForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross proceeds for services.", "label": "Percentage of gross proceeds raised for services" } } }, "localname": "GrossProceedsForServices", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "JWAC_IncomeTaxPayableCurrent": { "auth_ref": [], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income tax payable current.", "label": "Income tax Payable" } } }, "localname": "IncomeTaxPayableCurrent", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "JWAC_IncreaseDecreaseInAccruedExpensesRelatedParty": { "auth_ref": [], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued expenses related party.", "label": "IncreaseDecreaseInAccruedExpensesRelatedParty", "verboseLabel": "Accrued expense-related party" } } }, "localname": "IncreaseDecreaseInAccruedExpensesRelatedParty", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "JWAC_IncreaseDecreaseInAccruedFranchiseTaxesPayable": { "auth_ref": [], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued franchise taxes payable.", "label": "Franchise tax payable" } } }, "localname": "IncreaseDecreaseInAccruedFranchiseTaxesPayable", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "JWAC_JupiterWellnessAcquisitionCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jupiter Wellness Acquisition Corp [Member]", "label": "Jupiter Wellness Acquisition Corp [Member]" } } }, "localname": "JupiterWellnessAcquisitionCorpMember", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "domainItemType" }, "JWAC_JupiterWellnessInvestmentCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jupiter Wellness Investment Corp [Member]", "label": "Jupiter Wellness Investment Corp [Member]" } } }, "localname": "JupiterWellnessInvestmentCorpMember", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/PromissoryNoteDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "JWAC_ListingAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Listing amount.", "label": "IPO listing price" } } }, "localname": "ListingAmount", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "JWAC_ListingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Listing units.", "label": "IPO listing units" } } }, "localname": "ListingUnits", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "JWAC_ManagmentAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Management and Directors [Member]", "label": "Management and Directors [Member]" } } }, "localname": "ManagmentAndDirectorsMember", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "JWAC_NonCashAccretionForClassCommonStockToRedemptionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non Cash Accretion For Class Common Stock To Redemption Amount", "label": "NonCashAccretionForClassCommonStockToRedemptionAmount", "verboseLabel": "Accretion for Class A common stock to redemption amount" } } }, "localname": "NonCashAccretionForClassCommonStockToRedemptionAmount", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "JWAC_OfferingCostsAssociatedWithTheIpoPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Offering Costs Associated With The Ipo [PolicyTextBlock]", "label": "Offering Costs Associated with the IPO" } } }, "localname": "OfferingCostsAssociatedWithTheIpoPolicyTextBlock", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "JWAC_OverAllotmentUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Over allotment units.", "label": "Percentage of over-allotment units" } } }, "localname": "OverAllotmentUnits", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "JWAC_PartnersCapitalAccountPublicSaleOfUnitsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Partners Capital Account Public Sale Of Units Shares", "label": "Sale of 13,800,000 Units at IPO, shares" } } }, "localname": "PartnersCapitalAccountPublicSaleOfUnitsShares", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "JWAC_PercentageOWarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of warrants issued.", "label": "Representative Warrants percent" } } }, "localname": "PercentageOWarrantsIssued", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "JWAC_PostTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Post Transaction [Member]", "label": "Post Transaction [Member]" } } }, "localname": "PostTransactionMember", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "JWAC_PromissoryNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note [Text Block]", "label": "PROMISSORY NOTE" } } }, "localname": "PromissoryNoteTextBlock", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/PromissoryNote" ], "xbrltype": "textBlockItemType" }, "JWAC_PublicOfferingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Offering [Text Block]", "label": "PublicOfferingTextBlock", "verboseLabel": "Public Offering" } } }, "localname": "PublicOfferingTextBlock", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/PublicOffering" ], "xbrltype": "textBlockItemType" }, "JWAC_RepresentativeShares2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Representative shares.", "label": "Representative shares" } } }, "localname": "RepresentativeShares2", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "JWAC_RepresentativeWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Representative Warrants [Member]", "label": "Representative Warrants [Member]" } } }, "localname": "RepresentativeWarrantsMember", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "JWAC_RightsExchangeableForOneeighthOfOneShareOfClassCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rights, exchangeable for one-eighth of one share of Class A common stock.", "label": "Rights, exchangeable for one-eighth of one share of Class A common stock" } } }, "localname": "RightsExchangeableForOneeighthOfOneShareOfClassCommonStockMember", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "domainItemType" }, "JWAC_SellerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seller [Member]", "label": "Seller [Member]" } } }, "localname": "SellerMember", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "domainItemType" }, "JWAC_SharesIssuedAndOutstandingPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued and outstanding percent.", "label": "Shares issued and outstanding percent" } } }, "localname": "SharesIssuedAndOutstandingPercent", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "JWAC_StockIssuedDuringPeriodSharesToBeIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares to be issued during period.", "label": "Ccommon stock issuable, shares" } } }, "localname": "StockIssuedDuringPeriodSharesToBeIssuedForServices", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "JWAC_StockIssuedDuringPeriodValueAccretionForCommonStockToRedemptionAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Value Accretion For Common Stock To Redemption Amount", "label": "Accretion for Class A common stock to redemption amount" } } }, "localname": "StockIssuedDuringPeriodValueAccretionForCommonStockToRedemptionAmount", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "JWAC_StockIssuedDuringPeriodValueCommonStockSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Value Common Stock Subject To Possible Redemption", "label": "StockIssuedDuringPeriodValueCommonStockSubjectToPossibleRedemption", "verboseLabel": "Common stock subject to possible redemption" } } }, "localname": "StockIssuedDuringPeriodValueCommonStockSubjectToPossibleRedemption", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "JWAC_StockIssuedDuringPeriodValueCommonStockSubjectToPossibleRedemptionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Value Common Stock Subject To Possible Redemption Shares", "label": "Common stock subject to possible redemption, shares" } } }, "localname": "StockIssuedDuringPeriodValueCommonStockSubjectToPossibleRedemptionShares", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "JWAC_UnderwritingPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriting price per unit.", "label": "Underwriting price per unit" } } }, "localname": "UnderwritingPricePerUnit", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "JWAC_UnsecuredPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unsecured Promissory Note [Member]", "label": "Unsecured Promissory Note [Member]" } } }, "localname": "UnsecuredPromissoryNoteMember", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/PromissoryNoteDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "JWAC_WarrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [PolicyTextBlock]", "label": "Warrants" } } }, "localname": "WarrantsPolicyTextBlock", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "JWAC_WorkingCapitalLoans": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Working capital loans.", "label": "Working capital loans" } } }, "localname": "WorkingCapitalLoans", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "JWAC_WorkingCapitalLoansOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Working Capital Loans Outstanding", "label": "Working capital loans outstanding" } } }, "localname": "WorkingCapitalLoansOutstanding", "nsuri": "http://jupiterwellness.com/20230331", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r413", "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PromissoryNoteDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PromissoryNoteDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r210", "r434" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r143", "r210", "r423", "r434" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r143", "r210", "r423", "r424", "r434" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r436", "r450" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative", "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative", "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r13", "r390" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expense related party" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expense" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [ "r115", "r116", "r245", "r246", "r247", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r115", "r116", "r245", "r246", "r247", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r58", "r390", "r454" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r212", "r213", "r214", "r296", "r431", "r432", "r433", "r446", "r455" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": { "auth_ref": [ "r9", "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.", "label": "Reclassification from negative additional paid-in capital to accumulated deficit" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "verboseLabel": "Deferred underwriting fee" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "auth_ref": [ "r389", "r443", "r444", "r445" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.", "label": "Transaction costs" } } }, "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r82", "r106", "r126", "r155", "r158", "r160", "r162", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r228", "r230", "r244", "r267", "r328", "r390", "r401", "r439", "r440", "r451" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r103", "r111", "r126", "r162", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r228", "r230", "r244", "r390", "r439", "r440", "r451" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrust": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.", "label": "Company net proceeds of IPO and private placement sale", "verboseLabel": "Deposits into trust account" } } }, "localname": "AssetsHeldInTrust", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrustCurrent": { "auth_ref": [ "r427" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Cash and marketable securities held in Trust Account", "verboseLabel": "Assets held in trust current" } } }, "localname": "AssetsHeldInTrustCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r226", "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r37", "r39", "r226", "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Post transaction ownership" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r79", "r227" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "BUSINESS COMBINATION" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BusinessCombination" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combination Marketing Fee" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Capital": { "auth_ref": [ "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of total capital as defined by regulatory framework.", "label": "Banking regulation, total capital, actual" } } }, "localname": "Capital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalUnitsAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Shares authorized" } } }, "localname": "CapitalUnitsAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r22", "r105", "r377" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r22", "r68", "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r2", "r68" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase/(decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Federal depositoryh insurance amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r100", "r107", "r108", "r109", "r126", "r145", "r146", "r148", "r150", "r153", "r154", "r162", "r169", "r171", "r172", "r173", "r176", "r177", "r195", "r196", "r198", "r201", "r207", "r244", "r288", "r289", "r290", "r291", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r316", "r337", "r359", "r370", "r371", "r372", "r373", "r374", "r422", "r428", "r435" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets", "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "http://jupiterwellness.com/role/Cover", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative", "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "http://jupiterwellness.com/role/StatementsOfOperations", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Shares of Class A to purchase", "verboseLabel": "Representative warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrants to purchase shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r18", "r50", "r268", "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r73", "r167", "r168", "r376", "r438" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets", "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "http://jupiterwellness.com/role/Cover", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative", "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "http://jupiterwellness.com/role/StatementsOfOperations", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets", "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "http://jupiterwellness.com/role/Cover", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative", "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "http://jupiterwellness.com/role/StatementsOfOperations", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockConversionFeatures": { "auth_ref": [ "r96", "r97", "r98", "r208" ], "lang": { "en-us": { "role": { "documentation": "Description of common stock conversion feature. Includes, but is not limited to, conversion price; conversion right; timing of right; terms, event or change in circumstance causing contingency to be met or adjustment to conversion price or number of shares; manner of settlement upon conversion; and method of settlement.", "label": "Common stock, terms of conversion" } } }, "localname": "CommonStockConversionFeatures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockHeldInTrust": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of common stock held in trust.", "label": "Stock held in trust" } } }, "localname": "CommonStockHeldInTrust", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r391", "r392", "r393", "r395", "r396", "r397", "r398", "r431", "r432", "r446", "r453", "r455" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r57", "r316" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r9", "r57", "r316", "r334", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r57", "r270", "r390" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock value" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets", "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r52", "r93" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r11", "r54", "r55", "r83", "r84", "r129", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r251", "r382", "r383", "r384", "r385", "r386", "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/PromissoryNoteDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r45", "r46", "r178", "r251", "r383", "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Principal amount", "terseLabel": "Debt Instrument, Face Amount", "verboseLabel": "Debt principle amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative", "http://jupiterwellness.com/role/PromissoryNoteDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r17", "r129", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r251", "r382", "r383", "r384", "r385", "r386", "r429" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/PromissoryNoteDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Deposits": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.", "label": "Deposits into trust account" } } }, "localname": "Deposits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r118", "r135", "r136", "r137", "r138", "r139", "r144", "r145", "r148", "r149", "r150", "r151", "r240", "r241", "r264", "r276", "r379" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted net loss per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted net income (loss) per share" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r9", "r101", "r115", "r116", "r117", "r130", "r131", "r132", "r134", "r140", "r142", "r152", "r163", "r164", "r209", "r212", "r213", "r214", "r223", "r224", "r232", "r233", "r234", "r235", "r236", "r237", "r239", "r245", "r246", "r247", "r248", "r249", "r250", "r252", "r279", "r280", "r281", "r296", "r359" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r1", "r6" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair value of representative warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentCurrencies": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of the total value of investments that are currencies for a given category of investments for which net asset value per share is calculated.", "label": "Fair market value of net assets" } } }, "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentCurrencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareRedemptionRestrictionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of the total value of investments that cannot be redeemed because of a redemption restriction as of the statement of financial position date.", "label": "Company obligation to redeem" } } }, "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareRedemptionRestrictionPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r7", "r10" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r66", "r339" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r63", "r86", "r155", "r157", "r159", "r161", "r265", "r274", "r381" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net Income (loss) before income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net income (loss) per share:" } } }, "localname": "IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r90", "r99", "r141", "r142", "r156", "r218", "r225", "r278" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income taxes", "negatedLabel": "Income Tax" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfOperations", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r114", "r216", "r217", "r219", "r220", "r221", "r222", "r287" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r5" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Income tax payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r5" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expense" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r5" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expense" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeMoneyMarketDeposits": { "auth_ref": [ "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest earned on funds deposited in US domestic money market accounts.", "label": "Interest to pay dissolution expenses" } } }, "localname": "InterestIncomeMoneyMarketDeposits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r119", "r121", "r122" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of fees and commissions from banking, advisory, brokerage, and securities underwriting activities. Activities include, but are not limited to, underwriting securities, private placements of securities, investment advisory and management services, merger and acquisition services, sale and servicing of mutual funds, and other related consulting fees.", "label": "Underwriting commissions", "verboseLabel": "Underwriting discount and commission aggregate payable" } } }, "localname": "InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r126", "r162", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r229", "r230", "r231", "r244", "r314", "r380", "r401", "r439", "r451", "r452" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r62", "r85", "r273", "r390", "r430", "r437", "r449" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 (Deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders\u2019 (Deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r16", "r104", "r126", "r162", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r229", "r230", "r231", "r244", "r390", "r439", "r451", "r452" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesGainLoss": { "auth_ref": [], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Gain (Loss)", "negatedLabel": "Interest earned on marketable securities held in Trust Account" } } }, "localname": "MarketableSecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities Held in Trust Account" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketingExpense": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.", "label": "Business combination marketing fee", "verboseLabel": "Marketing fees" } } }, "localname": "MarketingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r120" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r120" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r68", "r69", "r70" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r64", "r70", "r87", "r102", "r112", "r113", "r117", "r126", "r133", "r135", "r136", "r137", "r138", "r141", "r142", "r147", "r155", "r157", "r159", "r161", "r162", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r241", "r244", "r275", "r336", "r357", "r358", "r381", "r399", "r439" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://jupiterwellness.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net Income (loss)", "verboseLabel": "Net Income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows", "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "http://jupiterwellness.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-Cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashMergerRelatedCosts": { "auth_ref": [ "r6" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.", "label": "Offering costs current liabilities" } } }, "localname": "NoncashMergerRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1": { "auth_ref": [ "r25", "r26", "r27" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Initial classification of ordinary shares subject to possible redemption" } } }, "localname": "NoncashOrPartNoncashAcquisitionInvestmentsAcquired1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBankCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.", "label": "Promissory Note - related party" } } }, "localname": "NotesPayableToBankCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r425" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Officers compensation" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative", "http://jupiterwellness.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://jupiterwellness.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expense" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expense" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r53", "r80", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION AND BUSINESS OPERATIONS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r65", "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other offering costs" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r67" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Income/(Expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNotesPayableCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Extension loan" } } }, "localname": "OtherNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PartnersCapitalAccountPrivatePlacementOfUnits": { "auth_ref": [ "r75", "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monetary value of the issuance of new units of limited partnership interest in a private placement.", "label": "Sale of 629,000 private units" } } }, "localname": "PartnersCapitalAccountPrivatePlacementOfUnits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PartnersCapitalAccountPublicSaleOfUnits": { "auth_ref": [ "r441", "r442" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monetary value of the issuance of new units of limited partnership interest in a public offering.", "label": "Sale of 13,800,000 Units at IPO" } } }, "localname": "PartnersCapitalAccountPublicSaleOfUnits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts": { "auth_ref": [ "r441", "r442" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after offering cost, from issuance of new unit of limited partnership interest in public offering.", "label": "Offering cost stockholders equity", "negatedLabel": "Offering Cost-Funds Flow" } } }, "localname": "PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PartnersCapitalAccountUnitsAcquisitions": { "auth_ref": [ "r40", "r41", "r42", "r43", "r75" ], "lang": { "en-us": { "role": { "documentation": "Change in the number of units for each class of partners' capital accounts during the year due to acquisitions. Partners include general, limited and preferred partners.", "label": "IPO Units", "verboseLabel": "IPO shares" } } }, "localname": "PartnersCapitalAccountUnitsAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement": { "auth_ref": [ "r75", "r77" ], "lang": { "en-us": { "role": { "documentation": "The number of units sold in a private placement of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.", "label": "Sale of 629,000 private units, shares", "terseLabel": "Private placement units", "verboseLabel": "Sale of private units, shares" } } }, "localname": "PartnersCapitalAccountUnitsSoldInPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficitParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PaymentsForUnderwritingExpense": { "auth_ref": [ "r4" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.", "label": "Underwriting discount and commission aggregate payable", "verboseLabel": "Underwriting expense payment" } } }, "localname": "PaymentsForUnderwritingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireTrustPreferredInvestments": { "auth_ref": [ "r426" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of trust preferred securities, which possess characteristics of both equity and debt securities.", "label": "Payments to Acquire Trust Preferred Investments", "negatedLabel": "Investment of cash in Trust Account" } } }, "localname": "PaymentsToAcquireTrustPreferredInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r391", "r392", "r395", "r396", "r397", "r398", "r453", "r455" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r56", "r195" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r56", "r316" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r56", "r195" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued", "verboseLabel": "Preferred stock issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r56", "r316", "r334", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding", "verboseLabel": "Preferred stock outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r56", "r269", "r390" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.0001 par value, 1,000,000 shares authorized, -0- shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r110", "r165", "r166", "r378" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expense" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDecommissioningFund": { "auth_ref": [ "r20" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of assets held in a decommissioning trust fund.", "label": "Proceeds from trust account" } } }, "localname": "ProceedsFromDecommissioningFund", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r3" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from issuance of public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r3" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of Units, net of underwriting discounts and offering expenses paid" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r3" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from sale of private units", "terseLabel": "Proceeds from issuance of private placement", "verboseLabel": "Generating gross proceeds" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative", "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r21" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from note payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfNotesPayable": { "auth_ref": [], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.", "label": "Proceeds (Repayment) to notes payable - related parties" } } }, "localname": "ProceedsFromRepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedAndNonrelatedPartyStatusAxis": { "auth_ref": [ "r127", "r128", "r256", "r257", "r258", "r259", "r309", "r310", "r311", "r312", "r313", "r333", "r335", "r394" ], "lang": { "en-us": { "role": { "documentation": "Information by related and nonrelated party status.", "label": "Related and Nonrelated Party Status [Axis]" } } }, "localname": "RelatedAndNonrelatedPartyStatusAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedAndNonrelatedPartyStatusDomain": { "auth_ref": [ "r127", "r128", "r256", "r257", "r258", "r259", "r309", "r310", "r311", "r312", "r313", "r333", "r335", "r394" ], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated party status." } } }, "localname": "RelatedAndNonrelatedPartyStatusDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyMember": { "auth_ref": [ "r127", "r128", "r256", "r257", "r258", "r259", "r309", "r310", "r311", "r312", "r313", "r333", "r335", "r366" ], "lang": { "en-us": { "role": { "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.", "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r340", "r341", "r344" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r253", "r254", "r255", "r257", "r260", "r293", "r294", "r295", "r342", "r343", "r344", "r363", "r365" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedInvestmentsPercentOfNetAssets": { "auth_ref": [ "r367", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "The percent of net assets of the aggregate value of all restricted investments.", "label": "Gross proceeds of the IPO" } } }, "localname": "RestrictedInvestmentsPercentOfNetAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r59", "r75", "r272", "r282", "r283", "r292", "r317", "r390" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated (deficits)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r101", "r130", "r131", "r132", "r134", "r140", "r142", "r163", "r164", "r212", "r213", "r214", "r223", "r224", "r232", "r234", "r235", "r237", "r239", "r279", "r281", "r296", "r455" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "auth_ref": [ "r8", "r44", "r81" ], "lang": { "en-us": { "role": { "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.", "label": "Sale of stock, description" } } }, "localname": "SaleOfStockDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Units at IPO, shares", "terseLabel": "Sale of units at IPO", "verboseLabel": "IPO Units" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative", "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficitParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Private placement equivalent units price", "terseLabel": "Sales units price per share", "verboseLabel": "Sale of stock units" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r33", "r78" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r47", "r48", "r340", "r341", "r344" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Shares purchase grant option" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Price per unit sold", "verboseLabel": "Share price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount that would be paid, determined under the conditions specified in the contract, if the holder of the share has the right to redeem the shares.", "label": "Common stock subject to possible redemption amount" } } }, "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r71", "r124" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r100", "r107", "r108", "r109", "r126", "r145", "r146", "r148", "r150", "r153", "r154", "r162", "r169", "r171", "r172", "r173", "r176", "r177", "r195", "r196", "r198", "r201", "r207", "r244", "r288", "r289", "r290", "r291", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r316", "r337", "r359", "r370", "r371", "r372", "r373", "r374", "r422", "r428", "r435" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets", "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "http://jupiterwellness.com/role/Cover", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative", "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "http://jupiterwellness.com/role/StatementsOfOperations", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r9", "r19", "r101", "r115", "r116", "r117", "r130", "r131", "r132", "r134", "r140", "r142", "r152", "r163", "r164", "r209", "r212", "r213", "r214", "r223", "r224", "r232", "r233", "r234", "r235", "r236", "r237", "r239", "r245", "r246", "r247", "r248", "r249", "r250", "r252", "r279", "r280", "r281", "r296", "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r130", "r131", "r132", "r152", "r263", "r286", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r316", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r335", "r338", "r339", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r359", "r394" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets", "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative", "http://jupiterwellness.com/role/Cover", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PromissoryNoteDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative", "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "http://jupiterwellness.com/role/StatementsOfOperations", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r130", "r131", "r132", "r152", "r263", "r286", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r316", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r335", "r338", "r339", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r359", "r394" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets", "http://jupiterwellness.com/role/BalanceSheetsParenthetical", "http://jupiterwellness.com/role/BusinessCombinationDetailsNarrative", "http://jupiterwellness.com/role/Cover", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PromissoryNoteDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative", "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit", "http://jupiterwellness.com/role/StatementsOfOperations", "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r9", "r56", "r57", "r75", "r288", "r359", "r371" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock issued during period, shares, new issues", "verboseLabel": "Shares purchased during period" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Class A units issued for Representative shares, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Shares issued as forfeited", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockSplits": { "auth_ref": [ "r9", "r56", "r57", "r75" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of a stock split.", "label": "Shares issued as split stock" } } }, "localname": "StockIssuedDuringPeriodSharesStockSplits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r9", "r56", "r57", "r75", "r296", "r359", "r371", "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Shares purchased during period, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Class A units issued for Representative shares" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r57", "r60", "r61", "r72", "r318", "r334", "r360", "r361", "r390", "r401", "r430", "r437", "r449", "r455" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Stockholders\u2019 (Deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets", "http://jupiterwellness.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 (Deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r74", "r125", "r194", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r209", "r238", "r362", "r364", "r375" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplit": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.", "label": "Stock split description" } } }, "localname": "StockholdersEquityNoteStockSplit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://jupiterwellness.com/role/OrganizationAndBusinessOperationsDetailsNarrative", "http://jupiterwellness.com/role/PublicOfferingDetailsNarrative", "http://jupiterwellness.com/role/RelatedPartyTransactionsDetailsNarrative", "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r169", "r171", "r172", "r173", "r176", "r177", "r215", "r271" ], "calculation": { "http://jupiterwellness.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Common stock subject to possible redemption" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Common stock subject to redemption" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r6" ], "calculation": { "http://jupiterwellness.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Unrealized loss from the trust account" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r28", "r29", "r30", "r91", "r92", "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrant measurement inputs" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "verboseLabel": "Warrant measurement inputs" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r144", "r150" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares outstanding, basic and dilutive shares" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding, basic and dilutive" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(1),20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.E.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)(1)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(7)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481648/480-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "05", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480153/805-50-05-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r402": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r403": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r404": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r405": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r406": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r407": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r408": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r409": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r411": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r412": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r413": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r414": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r415": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r416": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r417": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r418": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r419": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r421": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.12)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org//805/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(b))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.4)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 43 0001493152-23-018333-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-018333-xbrl.zip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�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�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�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end

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